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ABSTRACT 
Opioids are among the most effective and commonly prescribed analgesics for the 
treatment of acute pain after spinal cord injury (SCI). We have shown, however, that 
morphine administration in the early phase of SCI undermines locomotor recovery in a 
rodent contusion model. Based on our previous studies we hypothesize that morphine acts 
on classic opioid receptors to alter the immune response after SCI. Whether morphine 
increases or decreases the immune response after SCI remains unclear.  To address this, 
in the experiments presented here we outlined changes in the temporal expression of 
microglia and macrophages after SCI and morphine administration (Aim 1). We also 
explored whether morphine changed the innate function of these cells through the 
engagement of cell-signaling pathways linked to neurotoxicity in microglia and 
macrophages (Aim 2) or by interfering with the ability of microglia and macrophages to 
perform phagocytic functions (Aim 3).  
To test these aims, subjects were given a moderate spinal contusion injury, and on 
the day following surgery, half of the subjects were treated with morphine and the 
remaining subjects served as controls, receiving an equivalent volume of 0.9% saline. 
Subjects were euthanized on days 2, 4 or 8 (24 hrs after the final dose of morphine). A 
section of the injured spinal cord was collected and the tissue was enzymatically and 
mechanically dissociated to conduct all subsequent analysis.  
Our results show that morphine administration immediately after an SCI increases 
the number of activated microglia and macrophages exacerbating the immune response. 
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We also found that repeated administration of morphine increases MAPK signaling and 
dynorphin production by microglia/macrophages. Lastly, our data shows that morphine 
might be reducing the proportion of M2 phagocytic macrophages needed to promptly 
remove injury debris and dead cells. Further studies are needed to explore whether reduced 
macrophage phagocytic activity affects microglia function and increases cell death.  Given 
the clinical utility of opioid analgesics, it is imperative that we fully understand the effects 
of morphine in mediating the immune response after SCI. We must develop safe and 
effective therapeutic strategies for the use of opioids in pain management after SCI. 
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CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW 
Use of Opioids for Pain Management After Spinal Cord Injury 
After a spinal cord injury (SCI), patients experience complete or partial loss of 
motor function. In addition, people with an SCI are at risk of developing accompanying 
complications such as loss of bladder and bowel function, sexual dysfunction, neuropathic 
pain, and depression. Pain is frequently experienced within the first few hours following 
SCI, and can arise from trauma to the cord, damage to the spinal nerves, spinal fractures, 
or from concomitant peripheral injuries. Over half of the people living with SCI continue 
to experience pain for months and even years after the injury, and about one-third rate 
their pain as severe or neuropathic (Siddall et al. 1999; Siddall et al. 2003). Indeed, chronic 
pain is one of the most concerning outcomes of SCI and is one of the ailments patients 
want cured the most (Anderson 2004; Collinger et al. 2013; Lo et al. 2016).  
In addition to decreasing quality of life, pain can also slow the rate of motor 
learning and recovery in patients during rehabilitation (Mercier et al. 2017). In one study, 
healthy subjects had to learn a motor task with pain (capsaicin cream) or without pain. On 
test day, the pain-free group performed the task significantly better than the pain group 
subjects, despite there not being any differences among groups during the task acquisition 
phase (Bouffard et al. 2014). These results suggest that pain might interfere with motor 
learning and rehabilitation in SCI patients. In the laboratory, we can also study pain 




contusion injury. Pre-clinical studies show that spinally-contused rats that are exposed to 
additional noxious stimulation in the form of uncontrolled shocks, or administration of an 
irritant like capsaicin, experience greater cell loss, regain significantly less locomotor 
recovery, and are at a greater risk for developing chronic pain compared to control SCI 
animals (Joynes et al. 2003; Ferguson, Crown, and Grau 2006; Grau et al. 2006; Grau et 
al. 2017). These recovery deficits can be blocked with the administration of lidocaine to 
reduce neural excitability but not with pre-treatment with analgesics like morphine (Turtle 
et al. 2017). These data suggest that noxious pain-induced deficits after SCI have a 
neurophysiological component that extends beyond the distressing psychological effects 
of feeling pain. These animal and clinical studies highlight the profound impact that pain 
has on the prognosis of patients and emphasize the importance of implementing adequate 
early pain management strategies in the clinic (Strain et al. 2019). Further, effective pain 
management during the acute phase of the injury is not only important to improve the 
outcome of SCI, it is also crucial to reduce the risk of developing untreatable chronic pain 
(Katz and Seltzer 2009; Kyranou and Puntillo 2012).  
In the emergency room (ER), the standard protocol for treating pain in patients 
with an SCI is the same as used for any other trauma patient requiring hospitalization. 
Non-steroidal anti-inflammatory drugs (NSAIDs) and other analgesics are often 
administered to patients during the initial phase of injury to alleviate pain. In addition to 
this, a study found that 47.8% of trauma patients receive supplemental intravenous opioid 
analgesics within the first 3 hours of arriving to the ER (Neighbor 2004). Other reports 




in the study received at least one dose of opioid analgesics within the first 24 hours of 
arriving to the ER, with morphine administered to 80% of patients in the acute phase 
(Stampas et al. unpublished data). In fact, the use of opioids after SCI is so ubiquitous, 
that physicians have long assumed them to be safe and to not interfere with recovery. 
Unfortunately, clinical and pre-clinical studies indicate that, contrary to this belief, 
morphine can negatively impact the prognosis for recovery in SCI patients. 
 
Impact of Opioids on Recovery of Function after SCI 
Evidence suggests that even short-term administration of morphine during the 
acute phase of SCI can exacerbate the size of the injury, delay recovery, and ironically, it 
can increase pain in the years following the injury (Loram et al. 2012; Trevino, deRoon-
Cassini, and Brasel 2013; Grace et al. 2016). Indeed, our laboratory has repeatedly found 
that morphine given in the days following SCI significantly undermines locomotor 
function, increases cell death around the lesion and, increases chronic pain in rodents 
(Hook et al. 2007; Hook et al. 2009; Hook et al. 2011; Woller et al. 2012; Woller et al. 
2014; Aceves, Mathai, and Hook 2016; Aceves et al. 2017; Hook et al. 2017; Aceves et 
al. 2019). Similarly, in other laboratories, transient spastic paraparesis has been observed 
in rats that received intrathecal (i.t.) administration of morphine after a non-injurious 
interval of spinal cord ischemia (Kakinohana, Marsala, et al. 2003; Kakinohana, 
Fuchigami, et al. 2003; Nakamura et al. 2004; Fuchigami et al. 2006). This effect is 
reversible with naloxone, suggesting that an opioid-mediated mechanism might be 




Preliminary data from a collaboration between our laboratory and TIRR Memorial 
Herman Hospital also suggests that, like in our rodent SCI model, morphine may in fact 
worsen the prognosis for recovery in patients. In this study, the amount of morphine 
received within the first 24 hours after injury positively correlated with increases in 
reported pain by patients at one-year post-SCI (Stampas et al., unpublished data). Motor 
deficits have also been reported in case studies where i.t. morphine was used during 
surgical procedures. Lower extremity paralysis was recorded in some patients after 
receiving i.t. morphine administration at clinically relevant doses (30g) (Kakinohana, 
Marsala, et al. 2003). After observing these troubling deficits in patients, the same research 
group were able to replicate their findings using a rodent model (Kakinohana, Fuchigami, 
et al. 2003). In a different clinical study, inflammatory masses found at the tip of i.t. 
catheters used to deliver morphine were reported to induce paraplegia in a number of 
patients (Coffey and Burchiel 2002). Notably, the masses were not present when catheters 
were used to deliver saline or baclofen, suggesting that morphine not the i.t. catheters 
induced the inflammatory response. A prospective trial on the effects of morphine in the 
clinical setting is warranted to understand the full impact of opioid administration on the 
prognosis of people living with an SCI. 
Indeed, based on the evidence discussed above, it might be tempting to simply 
eliminate the use of opioids after SCI in the clinic. Unfortunately, pain management is not 
a straightforward process and physicians often have to employ a trial-and-error approach 
to find an effective regimen that works for their patients. Analysis of clinical pain 




combination of primary anesthetics (paracetamol, codeine, NSAIDs, and morphine) and 
59% receive a co-analgesic (antidepressants, anticonvulsants, vitamin B12, thiamine, 
prazosin, or mexiletine) demonstrating the wide range of treatments employed to 
accommodate for individual needs and responses to analgesics (New et al. 1997). There 
are a number of challenging inter-individual factors that complicate the establishment of 
successful pain management strategies. First, the number of comorbid conditions that 
regularly accompany SCI make it difficult to accurately rate pain levels and to determine 
whether pain sensation is due to a transient affliction (cuts and lacerations) or a persistent 
condition (nerve damage) (Cardenas et al. 2002; Warms et al. 2002; Cardenas and Jensen 
2006). In addition, the exact mechanism responsible for the progression of acute into 
chronic pain is not fully understood (Cardenas and Jensen 2006). Some contributing 
physiological elements include mechanical damage to nerves, aberrant activity of 
regenerating dorsal root ganglia in contact with nerve afferents, over-excitation of 
nociceptive A afferents, and central sensitization induced by peripheral inputs. 
Moreover, psychosocial elements like the state of anxiety of the patient and access to 
social support networks can also influence pain progression (Katz and Seltzer 2009). 
Given the myriad of inestimable elements that shape pain development, it is important that 
doctors can safely utilize every tool available in the clinic to improve the prognosis of 
people with SCI. Without better alternatives, opioids remain the most effective analgesics 
available in the clinic and are a valuable resource to patients experiencing severe pain that 
cannot be managed with other analgesics. It is crucial that we understand the full impact 




implement empirically-driven alternative pain management strategies that do not 
aggravate the injury. While the exact mechanism responsible for the negative effects of 
opioids is not fully understood, preliminary data from our laboratory suggests that 
morphine enhances spinal inflammation and exacerbates the secondary injury cascade. 
 
Opioid-Immune Interaction in Spinal Cord Injury  
Immediately after the injury, neuronal death occurs as a direct result of the 
mechanical impact to the spinal fibers – this is referred to as the primary injury. This initial 
trauma triggers a series of immune and physiological responses that further induce cell 
necrosis and extend the damage during the secondary phase of injury. Despite the many 
advances in the field of SCI, scientists are still largely unable to reverse damage to nerve 
fibers that occur during the primary injury. Therefore, current surgical and 
pharmacological interventions in the clinic are aimed at minimizing the expansion of the 
secondary injury cascade and alleviating symptoms associated with SCI (Casha et al. 
2012; Fehlings et al. 2015; Phang et al. 2015; Yue et al. 2017; Burke et al. 2019). Immune 
cells are a favored target of experimental and clinical trials. The immune response 
mediates most of the events that magnify secondary damage including hemorrhage, 
enzymatic lipid hydrolysis, permeation of the spinal cord-blood barrier, release of free 
radicals into the intracellular space, production of cytokines and chemokines, ischemia, 
and inflammation (Anderson and Hall 1993). While immune cell activation immediately 
after SCI prevents injury damage from expanding indiscriminately along the cord 




immune cells are reported to improve motor recovery after SCI (Bracken et al. 1990; 
Bracken et al. 1997; van Rooijen and Hendrikx 2010; Iannotti et al. 2011). Analogously, 
treatments that protract or augment the initial inflammatory response can delay injury 
resolution (Probert et al. 2000).  
Indeed, we have observed an increase in inflammatory cells at the injury site after 
a single intrathecal (i.t.) dose of morphine in SCI rats (Aceves et al. 2019). Upon further 
examination, we found that pre-treatment with the glia-inhibitor minocycline protects 
against the negative effects of morphine (Aceves et al. 2019). Interestingly, pre-treatment 
with Norbinaltorphimine (nor-BNI), a kappa opioid receptor (KOR) antagonist, also 
prevents the negative effects of morphine on motor recovery (Aceves, Mathai, and Hook 
2016; Aceves et al. 2017). Interactions between the immune and opioid systems have long 
been described in healthy and disease models, including SCI. Our research suggests that 
an opioid-immune interaction could be at the core of the negative effects that we observe 
in motor recovery after morphine administration. In fact, we believe that morphine-
induced inflammation is contributing to the surge in cell death that we see in our rodent 
model. We hypothesize that activation of opioid receptors (ORs) on microglia and 
macrophages changes the innate immune response to SCI and potentiates the 








Effects of Opioids on Immune Cell Populations 
 
Astrocytes, SCI, and Opioids 
The immune response consists of a complicated series of events tightly regulated 
by a soup of molecular signals. As discussed below, some of these events have the 
potential to be optimized to improve injury outcome while others exacerbate the injury 
damage. Therefore, any treatments that alter the immune response have to be approached 
with caution. After an SCI, damaged cells release pro-inflammatory cytokines and 
chemokines like interlukin-1 (IL-1) and tumor necrosis factor (TNF) that initiate the 
recruitment of resident glia and peripheral immune cells to the site of lesion (Mantovani, 
Bussolino, and Introna 1997). Resident astrocytes also become activated after an SCI and 
are some of the first type of cells to respond to the injury. Activated astrocytes along with 
fibroblasts infiltrate the lesion center and associate with inhibitory extracellular matrix 
components (EMC) such as laminin, fibronectin, and collagen (Beattie et al. 1997; Bruce 
et al. 2000; Orr and Gensel 2018). Astrocytes and fibroblasts then surround the lesion and 
deposit additional EMC components to form a fibrotic scar. EMC components of the scar 
tissue increase cellular production of matrix metralloproteases (MMPs) which in turn 
signal the recruitment of peripheral immune cells to infiltrate the injury (Goussev et al. 
2003; Ogier et al. 2006; Takenaga and Kozlova 2006; Yu et al. 2008; Zhang et al. 2011). 
Unfortunately, EMC components such as fibronectin and chondroitin sulfate 
proteoglycans (CSPGs) can also prevent axonal regeneration (Bush et al. 1999; Harris et 




scar would improve axonal growth, re-myelination, and functional recovery. However, a 
classic SCI paper by Faulkner et al. (2004) showed that complete obliteration of astrocytes 
resulted in widespread tissue damage, cell death, and greater motor deficits. As 
demonstrated by this study, the formation of the scar is essential for injury resolution. The 
scar traps neurotoxic agents, aids with debris removal, produces neurotrophins, and 
promotes spinal cord-barrier repair (Anderson et al. 2016).  
Alarmingly, opioid receptor activation can affect the proliferation of astrocytes.  
Morphine administration has been reported to decrease the proliferation of glia cells in ex 
vivo cultures of mouse cortex (Stiene-Martin and Hauser 1990; Hauser and Stiene-Martin 
1991; Zagon and McLaughlin 1991). Similarly, we have observed that in contused rats, 
repeated intravenous (i.v.) administration of morphine results in a dramatic decrease of 
the number of activated astrocytes at the center of the lesion 7 days after the injury (Hook 
et al. 2017). Conversely, other laboratories find that activation of KORs in pituitary and 
spinal astrocytes increases their proliferation (Bunn, Hanley, and Wilkin 1985; Xu et al. 
2007).  It is possible that the discrepancy in results is due to variations related to 
anatomical regions, the timepoint at which proliferation is assayed, or the use of different 
cell lines. Additionally, a particular ligand can preferentially activate signaling pathways 
that might differ from the activation pathway exerted by a different ligand binding to that 
same receptor – a phenomenon known as biased agonism.  In one study, the KOR agonist 
U69593 increased the proliferation of astrocytes, while a different KOR agonist, MOM-
Sal-B, a non-nitrogenous agonist, did not affect proliferation in the same population of 




downstream signaling pattern and can override each other’s activation signals in some 
cases. For instance, in glioma cells in vitro, pre-treatment with a MOR agonist will 
suppress KOR-mediated ERK phosphorylation and prevent cell proliferation (Bohn et al., 
2000). Similarly, MOR and KOR agonists activate the ERK/MAPK signaling pathway in 
astrocytes but they are thought to do it through different upstream secondary messengers, 
which leads to short (DAMGO – 30 min) vs. prolonged (U69,593 - hours) ERK activation 
(Belcheva et al. 2005). We cannot base our understanding of the function of morphine on 
the effects reported through the use of other opioid agonists.  
In addition to influencing cell proliferation, morphine can also disrupt the 
communication between astrocytes and other immune cells after an injury. For instance, 
after SCI, morphine administration promotes the release of extracellular vesicles by 
astrocytes. These vesicles are then taken up by microglia to be processed within the 
endosomes and subsequently decreasing microglial phagocytosis while increasing the 
production of pro-inflammatory cytokines (Hu et al. 2018). Disruption of this process is 
important as it has the potential to change the inflammatory response to SCI and affect 
recovery in patients.  
 
Microglia and Macrophages, SCI, and Opioids 
Besides activating astrocytes, cellular debris releases damage-associated 
molecular patterns (DAMPs) that signal the activation of resident microglia. After an SCI, 
microglia perform key phagocytic and debris removal functions around the injury. 




growth factors, and inflammatory signals that aid with the recruitment of infiltrating 
macrophages and neutrophils to the site of injury. Neutrophils provide a line of defense 
against bacterial invasion and perform supplementary phagocytic functions after SCI. 
Infiltrating neutrophils are short-lived and peak around 24-hours after the injury (Carlson 
et al. 1998). Similar to the astrocytic response, there is conflicting evidence on whether 
neutrophil infiltration improves injury resolution or whether by-products, like oxidative 
species that are derived from neutrophil-mediated functions, exacerbate SCI pathology 
(Donnelly and Popovich 2008; Orr and Gensel 2018). Infiltrating macrophages on the 
other hand, peak between three and seven days after the injury (Popovich, Wei, and Stokes 
1997) but in humans can remain at the lesion site for months, and even years according to 
some reports (Fleming et al. 2006). The morphology and function of macrophages overlap 
extensively with those of microglial cells. In fact, macrophages and microglia share so 
many traits that they are practically indistinguishable in the spinal cord through 
morphology alone (David and Kroner 2011).  
 Microglia and macrophages are of special interest in the field of SCI because of 
the large body of literature showing seemingly contradictory narratives about the role of 
these cells after injury.  Activated microglia and macrophages produce neuroprotective 
factors like transforming growth factor- (TGF-) and macrophage colony stimulating 
factor receptor (M-CSFR) that have been reported to improve recovery in rats after SCI 
(Wiessner et al. 1993; Tyor et al. 2002; Buss et al. 2008; Mitrasinovic et al. 2005). 
Clearance of apoptotic debris by microglia and macrophages also reduces the production 




and myelin debris release inhibitory molecules that prevent axonal regeneration 
(Takahashi, Rochford, and Neumann 2005; Vallieres et al. 2006). The transplantation of 
activated macrophages into the injured tissue after SCI has also been reported to improve 
recovery, bolstering the argument for their beneficial role in SCI (Lazarov-Spiegler et al. 
1996; Rapalino et al. 1998; Schwartz et al. 1999).   
On the other hand, microglia and macrophage infiltration to the injury has also 
been shown to increase secondary cell death, neuronal loss, and demyelination (Popovich 
et al. 1999; Nishio et al. 2009). After SCI, microglia and macrophages produce pro-
inflammatory cytokines like interlukin-1 (IL-1), tumor necrosis factor- (TNF-), and 
interlukin-6 (IL-6) which are particularly cytotoxic to vulnerable neurons (Yang et al. 
2004; Longbrake et al. 2007; Pineau and Lacroix 2007). In fact, blocking IL-1 and TNF-
, or preventing TNF- binding to neurons, reduces inflammation, decreases apoptosis, 
and improves recovery after SCI (Nesic et al. 2001; Ferguson et al. 2008; Genovese et al. 
2008; Hook et al. 2011). Microglia and macrophages also produce reactive oxygen species 
(ROS) and nitrogen species (iNOS) which further increase cell death after SCI 
(Chatzipanteli et al. 2002; Pearse et al. 2003; Bao et al. 2009). Incongruities between the 
harmful versus beneficial effects of microglial and macrophage activation can be due to 
differences in the timepoint at which the immune response was assayed (or targeted), and 
the state of polarization of microglia and macrophages at that time. After SCI, activated 
microglia and macrophages acquire either a classic M1 (pro-inflammatory) or alternative 
M2 (reparatory) phenotype. However, the variability of current markers available to 




to differentiate between the two phenotypes when describing the functions of activated 
microglia/macrophages.   
Unfortunately, our data suggests that in our SCI model microglia and macrophages 
might actually mediate the mechanism responsible for the harmful effects of morphine 
after SCI. In our rodent model of spinal contusion, we have seen an increase in the total 
number of activated microglia and macrophages at the site of the lesion after a single 
intrathecal administration of morphine. More importantly, we have also shown that pre-
treatment with the glia-inhibitor minocycline prevents the over-expression of these 
immune cells and blocks the negative effects of morphine on recovery of locomotion 
(Aceves et al. 2019). It has long been established that opioids, including morphine, can 
affect microglia/macrophage signaling and function by activating receptors found on the 
surface of these cells. For example, agonizing non-classic TLR4 opioid receptors, 
increases pro-inflammatory signals that mediate maladaptive pain hypersensitivity, and 
initiate apoptotic cascades (O'Neill 2008; Buchanan et al. 2010). OR activation also 
triggers the ERK 1/2 pathway which is an upstream kinase responsible for CREB 
regulation of dynorphin gene expression (Kreibich and Blendy 2004). Dynorphin A, the 
endogenous ligand of KOR, is particularly important in SCI research because it is naturally 
upregulated during nerve injury in response to pain signaling. However, whereas neuronal 
production of Dynorphin promotes analgesia, glia-mediated production of Dynorphin A 
contributes to the development of allodynia (Xu et al. 2004; Zhu et al. 2006). Dynorphin 
can also induce neurotoxicity at elevated levels, causing motor dysfunction in uninjured 




can block these effects (Faden 1990). Interestingly, our laboratory has also found that 
pretreatment with nor-BNI (Aceves et al. 2017) blocks the morphine-induced motor 
deficits. In addition, activation of classic opioid receptors (ORs) (Kappa, Mu, and Delta) 
on glia cells can induce the p38 MAPK pathway which has been shown to play a role in 
inflammation (Tibbles and Woodgett 1999) and in the production of pro-inflammatory 
cytokines like IL-1β, IL-6, TNF-a, and nitric oxide synthase (Ashwell 2006). Interestingly, 
IL-1β is only neurotoxic when added to neurons in the presence of glia cells but does not 
induce toxicity if added to neurons alone (McNamee et al. 2010). This evidence strongly 
suggests that morphine has a neurotoxic effect after the injury.  
Alarmingly, morphine has also been reported to reduce the phagocytic function of 
microglia and macrophages, which can delay injury resolution and exacerbate 
inflammation (Rojavin et al. 1993; Hu et al. 2018). Myelin debris produces inhibitors of 
axonal growth signals (Schnell and Schwab 1990; Schwab 1990; Mukhopadhyay et al. 
1994) and slows debris clearance by macrophages which impedes axonal extension and 
remyelination (Imai et al. 2008; Perry, Brown, and Gordon 1987). A morphine-induced 
delay of the phagocytic response along with increases in production of pro-inflammatory 
factors could explain some of the mechanisms responsible for the locomotor deficits we 
see in our SCI rodent model.  
Studies from our laboratory in combination with the existing literature, support the 
notion that opioid-immune interactions play a fundamental role in producing the negative 
effects of morphine. Morphine is typically regarded as a Mu opioid receptor (MOR) 




studies, morphine can still bind to and activate the rest of the classic and non-classic opioid 
receptors to a lesser degree. Indeed, we find that in our model activation of KORs is 
sufficient and necessary to mediate the negative effects of morphine on recovery (Aceves 
et al. 2017; Aceves, Mathai, and Hook 2016), suggesting that even weak activation of 
receptors can have significant functional consequences. Nonetheless, while our effects 
seem to be primarily mediated by KORs, it is important to recognize that morphine will 
invariably activate other opioid receptor subtypes around the injury and that this activation 
can further impact recovery of function. Thus, the primary objective of this project is to 
identify critical opioid-immune interactions that undermine recovery of function in our 
rodent model of SCI. 
 
Specific Aims 
In the days following SCI, morphine administration undermines locomotor recovery, 
expands the size of the injury, exacerbates cell death, and increases mortality in rodents. 
We believe that morphine administration disrupts the immune response in the early phase 
of the injury, augmenting the secondary injury cascade and creating a toxic cellular 
environment. This hypothesis is based on previous data from our laboratory showing that 
a single dose of intrathecal morphine after a spinal contusion injury increases the number 
of microglia and macrophages at the lesion site. We have also shown that pre-treatment 
with the glia-inhibitor minocycline prevents the negative effects of morphine on recovery 
of function. It is well known that opioids can modulate microglia and macrophages by 




morphine can affect the development of the inflammatory response. Our previous studies 
have also shown that activation of the KOR is necessary and sufficient for the morphine-
induced attenuation of locomotor recovery (Aceves et al. 2016, 2017). The nature of the 
molecular interaction between KORs and microglia/macrophages, however, is also not 
known. The aim of the experiments outlined in Chapters 3-5 was to characterize the 
changes in expression and function of microglia/microglia with intravenous morphine 
administration, a more clinically relevant paradigm, as well as further examining the 
interactions between KORs and immune cells during the acute phase of SCI.  
Based on the literature, we know that activation of different ORs on immune cells 
can induce signaling pathways related to proliferation, apoptosis, cytokine production, and 
phagocytic activity of these cells. However, the extent to which intravenous morphine 
administration will alter these key functions to delay injury resolution is less understood. 
To address this, I completed the following aims: 
Specific Aim #1: Outline the changes in the temporal expression of microglia and 
macrophages after SCI and IV morphine administration.  Our working hypothesis is 
that morphine in the acute phase of the injury increases the number of activated 
microglia/macrophages and will bias their polarization towards an M1 pro-inflammatory 
profile. As discussed previously, upon activation microglia and macrophages typically 
acquire an M1 (pro-inflammatory), an M2 (anti-inflammatory), or in some cases a mixture 
of both phenotypes based on the signals they encounter at the lesion. Differentiating 
between the two cells types could help elucidate the dualistic nature of these immune cells 




function after an SCI. To address this, in the first set of experiments outlined in Chapter 
3, I evaluated the changes in the temporal expression of M1/M2 microglia and 
macrophages after morphine administration and the expression of KORs on each cell 
subtype. 
Specific Aim #2:  Determine whether morphine engages cell-signaling pathways 
linked to neurotoxicity in microglia and macrophages. Our working hypothesis is that 
the activation of opioid receptors on immune cells by morphine initiates signaling 
pathways responsible for inflammation and neurotoxicity. Regardless of whether 
morphine enhances the innate expression of ORs by immune cells, we know that morphine 
can bind to classic opioid receptors (Bunn, Hanley, and Wilkin 1985; Eriksson et al. 1993) 
and initiate context-dependent molecular cascades, that in some cases induce 
neurotoxicity (Belcheva et al. 2005; Bruchas et al. 2006; Bruchas and Chavkin 2010).  OR 
activation on glia cells induces the p38 MAPK pathway (Bruchas et al. 2006; Bruchas et 
al. 2007; Xu et al. 2007) which is a stress-responsive pathway that modulates processes 
like apoptosis, immune activation, and inflammation (Tibbles and Woodgett 1999; 
Bruchas and Chavkin 2010). OR activation can also trigger the ERK 1/2 pathway which 
is an upstream kinase responsible for CREB regulation of dynorphin gene expression 
(Kreibich and Blendy 2004). Dynorphin, the endogenous KOR agonist, can induce 
neurotoxicity at elevated levels, causing motor dysfunction in uninjured rats when 
administered intrathecally (Faden 1990). Therefore, in the experiments in Chapter 4, I 
assessed the expression of key proteins within inflammatory and apoptotic signaling 




Specific Aim #3: Investigate the extent to which morphine interferes with the 
ability of microglia and macrophages to perform their crucial phagocytic function. 
Our working hypothesis is that morphine decreases the phagocytic capacity of microglia 
and macrophages delaying injury resolution. Morphine has been reported to reduce the 
phagocytic function of microglia and macrophages in vitro and in vivo (Rojavin et al. 
1993; Hu et al. 2018). Phagocytosis is one of the most crucial functions performed by glia 
since delayed removal of injury debris and damaged cells increases inflammation and 
neurotoxicity. In the last group of experiments in Chapter 5, I investigated the extent to 
which morphine interferes with the phagocytic activity of microglia and macrophages.  
In sum, the primary goal of the experiments described in this thesis was to contribute 
to the basic understanding of opioid-immune interactions in the context of spinal cord 
injury. We must understand the molecular consequences of opioids to develop safe and 









The subjects used in the following experiments were male Sprague Dawley rats 
obtained from Harlan (Houston, TX) between 90 and 110 days old (300-350 g). Rats were 
single-housed in plexiglass cages (45.7 (length) x 23.5 (width) x 20.3 (height) cm) with 
food and water available ad libitum. Following a contusion (or sham) surgery body 
weights were recorded daily. Subjects that received the contusion surgery also lost bladder 
function and were manually expressed daily in the morning (7:00–9:30) and evening 
(16:30–18:00) until an empty bladder was observed for 3 consecutive days. A 12-h 
light/dark cycle was maintained, with behavioral testing conducted during the light cycle. 
All of the experiments were reviewed and approved by the Institutional Animal Care and 
Use Committee at Texas A&M University and all NIH guidelines for the care and use of 
animal subjects were followed. 
 
Jugular Catheter Surgery 
A jugular catheter was implanted 5 days prior to the contusion injury to deliver 
drugs intravenously. Briefly, anesthesia was induced with isoflurane at a level of 5% gas 
and lowered to 2-3% to maintain a stable level of anesthesia in rats. The subject’s back 
and neck area were shaved and disinfected with iodine. A horizontal 4 cm incision was 




subcutaneous tunnel beginning at the large opening in the back, traveling over the 
shoulder, and ending at the neck was made by carefully separating the skin from the 
muscle using forceps. Next, a 1 cm superficial incision was made directly above the 
jugular vein and connective tissue was carefully cleared away from the vein to allow for 
insertion of the catheter.  The sterilized catheter consisting of Silastic tubing (0.025-mm 
ID) was inserted through the incision in the back and passed subcutaneously over the right 
shoulder to reach the opening at the neck. Before insertion, the catheter was flushed with 
sterile saline by attaching a syringe to the catheter’s cannula; the syringe remained 
attached to the catheter for the duration of the surgery.  The Silastic tubing was inserted 
into the vein using an 18-G needle as a guide and kept in place by tying loose knots to 
both ends of the jugular vein. Successful placement of the intravenous (i.v.) line was 
confirmed by pulling on the syringe attached to the catheter to draw back blood.  The 
back-mount pedestal (model 313-00BM-10-SPC; Plastics One Inc., Roanoke, VA) 
connected to the catheter was implanted subcutaneously and the tip of the catheter’s 
cannula was allowed to exit the skin through a small opening at the back between the 
scapulae. All wounds were closed using Michel clips. After the surgery, the catheter was 
flushed with 15ul of heparin-saline (1000 units/mL) and immediately capped to prevent 
the formation of blood clots inside the tubing.  For the first 24 h after surgery, rats were 
placed in a recovery room maintained at 26.6°C. To compensate for fluid loss, subjects 







Subjects received a moderate contusion injury using the Infinite Horizon (IH) 
spinal cord impactor (PSI, Fairfax Station, VA, USA). Briefly, subjects were anesthetized 
with isoflurane (5%, gas), and after a stable level of anesthesia was reached, the 
concentration of isoflurane was lowered to 2–3%. The subject’s back was shaved and 
disinfected and a 5.0 cm incision was made over the spinal cord. Two incisions were made 
along the vertebral column, on each side of the dorsal spinous processes, extending about 
2 cm rostral and caudal to the T12 segment. The musculature and connective tissue around 
the transverse processes was cleared to allow for clamping of the vertebral spinal column. 
Next, the dorsal spinous process at T12 was removed (laminectomy), and the spinal tissue 
exposed. The dura remained intact. The vertebral column was fixed within the IH device 
using two pairs of Adson forceps. A moderate injury was produced using an impact force 
of 150 kdynes and a 1 sec dwell time. The wound was closed using Michel clips. For the 
first 24 h after surgery, the rats were placed in a recovery room maintained at 26.6 °C. To 
compensate for fluid loss, subjects were given 3 ml of saline after surgery.  
 
Assessment of sensory reactivity 
 
Thermal Reactivity 
To assess acute drug efficacy, the tail-flick test (D'amour and Smith, 1941; Jeffrey 
et al., 2001; Šedý et al., 2008) of thermal reactivity was conducted immediately before 




acclimate to the tail-flick apparatus (IITC Life Science Inc., Woodland Hills, CA, USA) 
and testing room (maintained at 26.5 °C) for 10 min. Prior to testing, the temperature of 
the light, focused on the tail, was set to elicit a baseline tail- flick response in 
approximately 4 s in an intact rat. This pre-set temperature was maintained across all SCI 
subjects. In testing, the latency to flick the tail away from the radiant heat source (light) 
was recorded. If a subject failed to respond, the test trial was automatically terminated 
after 8 s of heat exposure. Two tests occurred at 2 min intervals, and the last tail-flick 
latency time was recorded.  
 
Tactile Reactivity 
Mechanical reactivity was tested by applying von Frey filaments (Semmes- 
Weinstein Anesthesiometer, Stoelting Co., Chicago, IL, USA) to the plantar surface of the 
hind paws, as previously described (Grau et al., 2004; Šedý et al., 2008). Filaments of 
increasing diameter (indicative of force applied) were briefly pressed against the rat’s paw 
until they exhibited a motor (handsaw withdrawal) and vocal response. The intensity of 
the stimuli that produced a response was reported using the formula provided by Semmes-
Weinstein: Intensity = log10 (10,000 * G force). If one or both responses (motor and 
vocal) were not observed, testing was terminated at a force of 300g. Tests of mechanical 
and thermal reactivity were conducted immediately before and 30 minutes after treatment 






Assessment of Locomotor Recovery 
Locomotor behavior was assessed once a day, starting 24 hours post-injury, using 
the Basso, Beattie and Bresnahan (BBB) scale (Basso et al., 1995) in an open enclosure (a 
blue children’s wading pool, 99 cm in diameter, 23 cm deep). Baseline motor function 
was assessed daily starting the day following injury and prior to drug treatment. Subjects 
were placed in the open field and observed for 4 min. Care was taken to ensure that all 
investigators’ scoring had high intra- and inter- observer reliability (all r’s > 0.89) and that 
they were blind to the subject’s experimental treatment. 
 
Intravenous Drug Administration 
Drug administration began 24 hours following the contusion injury, after 
performing baseline tests for locomotor function, thermal reactivity, and mechanical 
reactivity. Baseline BBB scores were balanced across groups. All drugs (morphine, saline, 
and heparin-saline) were administered via the i.v. catheter. Half of the subjects in each 
injury condition were treated with 10 mg of morphine (i.v.) on days 1-2, 20 mg on days 
3-4, and 30 mg on days 5-7. Morphine was administered in 5 mg doses at 1-hour intervals 
up to the total daily dose. As we have done in previous studies, we selected our dosage of 
morphine to mirror the rate of administration observed in rats when they are allowed to 
self-administer intravenous morphine after an SCI (Woller et al. 2014).  The remaining 
subjects served as controls, receiving an equivalent volume of vehicle (0.9% sterile saline) 
on the same schedule as the morphine-treated subjects. Heparin-saline (1000 units/mL) 




current study were derived from previous experiments assessing analgesia, self- 
administration, and cell expression after SCI (Woller et al. 2012; Hook et al. 2017). 
 
Tissue Collection and Cell Dissociation 
Subjects were euthanized on days 2, 4, or 8 (24 hrs after the final dose of morphine 
given on days 1, 3, or 7). For western blot analysis, an additional collection timepoint was 
made on day 3 (30 minutes after the final morphine administration). Subjects were deeply 
anesthetized (100 mg/kg of beuthanasia, i.p.) and perfused intracardially with 100 ml of 
cold 1X PBS. A 1.5 cm segment of the lesioned spinal cord was collected, or the equivalent 
area for sham subjects. To prepare the tissue for both flow cytometry and western blot 
analysis, the spinal tissue was mechanically dissociated using a blade and washed in 1X 
HBSS. Cells were retrieved by centrifugation (500xG, 5 min, 4 °C). The cell suspension 
was then enzymatically (Neural Tissue Dissociation Kit (P) (Miltenyi Biotec, Germany) 
and mechanically dissociated using a dounce homogenizer with a loose pestle. The 
resulting cell suspension was washed twice with 1X HBSS and resuspended in 3 mL of 
1X HBSS. The 3 mL suspension containing a heterogeneous mixture of dissociated cells 
(i.e. inflammatory cells, glia, and neurons) was filtered through a 70-micron cell strainer, 
washed twice, and counted (Countess; Life Technologies, Carlsbad, CA, USA).  
 
Flow Cytometry 
Flow cytometry was used to quantify immune-competent cells at the lesion site.  




300,000 cells/well were plated in a round bottom 96-well plate and resuspended in 100 
L of staining buffer (BioLegend, San Diego, CA, USA) in preparation for 
immunostaining. The cells were then incubated with antibodies according to Table 1. For 
each subject, 2 technical replicates were prepared per set and phenotyped using a 
FACSFortessa flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA). A total of 
100,000 events per sample were recorded and the data was analyzed using FlowJo 



















Table 1. List of antibodies used for Aim 1 flow cytometry 
Antibody Concentration Manufacturer 
Set 1 – Pro-inflammatory: M1 Phenotype 
CD11b conjugated to biotin 1:1000 ThermoFisher 
CD45 conjugated to eFluour450 1:100 ThermoFIsher 
Rabbit monoclonal to Kappa Opioid 
Receptor 
1:500 Abcam 
CD86 conjugated to FITC 1:100 ThermoFisher 
Zombie NIR (Live/Dead Stain) 1:500 BioLegend 
NeutrAvidin  conjugated to Alexa 594 1:50 Abcam 
Goat anti-rabbit Alexa 750 1:1000 ThermoFisher 
   
Set 2 – Phagocytic: M2 Phenotype 
CD11b conjugated to FITC 1:1000 ThermoFisher 
CD45 conjugated to eFluour450 1:100 ThermoFisher 
Rabbit monoclonal to Kappa Opioid 
Receptor 
1:500 Abcam 
CD206 conjugated to biotin 1:50 Antibodies Online 
Zombie NIR (Live/Dead Stain) 1:500 BioLegend 
NeutrAvidin  conjugated to Alexa 594 1:50 Abcam 




Magnetic-Activated Cell Sorting (MACS) 
For western blot analysis, microglia and macrophages were separated from a 




The single-cell suspension obtained from spinal tissue was incubated for 15 mins with 
anti-CD11b magnetic beads (Miltenyi Biotec, Germany). After incubation, the suspension 
was rinsed with 10% BSA to remove unattached CD11b beads. The cells were 
resuspended in 3 mL of 10% BSA and passed through magnetic separation columns 
(Miltenyi Biotec, Germany) where CD11b+ cells were trapped while all other cells flowed 
freely out of the column. Unlabeled cells were collected as they exited the column as the 
“negative fraction”. The “positive fraction” or CD11b+ (microglia and macrophages) cells 
were extracted from the column by removing the magnetic separation column from the 
magnetic stand and flushing the cells out using the supplied plunger and 10% BSA.  
 
Western Blots 
Western blots were utilized as a semi-quantitative assay of proteins pertaining to 
opioid receptor signaling pathways of interest. The isolated CD11b+ (microglia, 
macrophages) effluent fractions obtained after MACS separation was collected. Cells 
were incubated in 1X RIPA with 1% Halt Protease Inhibitor Cocktail buffer at 4 °C for 30 
minutes. Cells were centrifuged (20,000xG for 10 min at 4 °C), and the supernatant 
containing the protein was extracted for western blot analyses. The protein concentration 
was calculated using the Pierce BCA Protein Assay Kit and measured with a NanoDrop 
spectrophotometer. Samples from 2 subjects belonging to the same treatment group were 
pooled together to obtain sufficient protein to perform the analysis. Fifteen g of protein 
(mixed with 5 L of loading dye, 1 g of reducing agent, and MilliQ water) were loaded 




for 200 minutes), and transferred to PVDF membranes with the iBlot Dry Blotting 
System (Invitrogen by Thermo Fisher Scientific, Waltham, MA, USA). The membranes 
were rinsed with 1X TBST and left to dry overnight. The PVDF membranes were 
reactivated by adding 2 mL of 100% methanol for 1 minute and rinsing them with MilliQ-
grade water.  Membranes were stained with REVERT Total Protein Stain (LI-COR 
Biosciences, Lincoln, NE, USA) to enable normalization of target signals. Staining of 
target proteins was done using the iBind Flex Western System (Invitrogen by Thermo 
Fisher Scientific, Waltham, MA, USA) and the antibodies listed in Table 2. All fluorescent 
detection of western blots was done with a LI-COR detection system and the data was 















Table 2. List of antibodies used for Aim 2 western blots 
Antibody Concentration Manufacturer 
Unconjugated Primary Antibodies   
-arrestin 1:100 Abcam 
p38 1:500 Abcam 
Dynorphin  1:100 ThermoFisher 
(ERK 1/2) 1:500 ThermoFisher 
Kappa Opioid Receptor 1:50 Abcam 
 1:1000  
Secondary Antibodies (LI-COR Biosciences) 
NeutrAvidin  conjugated to Alexa 594 1:2000 LI-COR Biosciences, Lincoln, NE 
Goat anti-rabbit Alexa 750 1:2000 LI-COR Biosciences, Lincoln, NE 
 
 
Phagocytosis Assay of Fluorescent Beads 
The isolated CD11b+ (microglia/macrophages) effluent fractions were collected 
and kept on ice to slow down cell degradation until they were ready for incubation. The 
cell pellet was resuspended in growth media consisting of 10% Fetal Bovine Serum (FBS) 
+ Dulbecco’s Modified Eagle’s Medium (DMEM), 50 L of Kanamycin (62mg/ml), 50 
l of Ampicillin (125mg/kg), and 500 l of Pen-Strep. Cell numbers were estimated using 
a Countess® Automated Cell Counter (ThermoFisher Scientific, MA, USA). One hundred 
l of media containing approximately 80,000 cells were then plated in a round bottom 96-
well plate. Cells were left in a 37C incubator at 5% CO2 for 30 minutes to allow the cells 
to settle and re-activate. Cells were then incubated for 2 hours with FITC-coated beads 




dilution following the methods described by Rustenhoven et al. (2016). Following 
incubation, any fluorescent beads that did not get phagocytosed were removed by 
performing 3X washes with 1X PBS. Cells were then stained with fluorescent antibodies 
for CD11b, CD45, CD68 (M1 marker), and MHCII (M2 marker) as shown in Table 3. For 
each subject, 2 technical replicates were prepared per set and phenotyped using a 
FACSFortessa flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA). A total of 
















Table 3. List of antibodies used for Aim 3 flow cytometry 
Antibody Concentration Manufacturer 
Set 1 – Pro-inflammatory: M1 Phenotype 
CD11b conjugated to Alexa Fluor 594 1:100 Abcam 
CD45 conjugated to eFluour450 1:100 ThermoFisher 
CD68 conjugated to PE-Vio 770 1:100 BioLegend 
Zombie NIR (Live/Dead Stain) 1:500 BioLegend 
Fluoresbrite® YG Carboxylate microspheres 1:1000  
   
Set 2 – Phagocytic: M2 Phenotype 
CD11b conjugated to Alexa Fluor 594 1:100 Abcam 
CD45 conjugated to eFluour450 1:100 ThermoFisher 
MHC II conjugated to PerCP-eFluor 710 1:250 AntibodiesOnline 
Zombie NIR (Live/Dead Stain) 1:500 BioLegend 





Flow cytometry, western blot, and sensory reactivity results were analyzed using 
two-way ANOVAs to examine the effect of surgery and drug treatment. When main 
effects were found to be significant, the Holm-Šídák test was used for post-hoc analyses. 
For experimental groups where only contused subjects were included, the results were 
analyzed using an unpaired t-test to compare drug treatment.  
Locomotor scores, collected using the BBB scale, were transformed as described 




amendable to parametric analyses. In short, this transformation removes a discontinuity in 






CHAPTER III  




As discussed in Chapter I, opioids remain as some of the most commonly 
administered analgesics for patients with an SCI, due to their efficacy to treat acute pain. 
However, despite their usefulness, clinical and pre-clinical studies suggest that opioids 
could undermine the recovery of function after an SCI. Given the limited number of 
alternative analgesics, it is crucial that we develop a better understanding of the molecular 
consequences of activating opioid receptors within the highly inflammatory context of 
SCI.  
While the exact mechanisms responsible for the negative effects of morphine are 
not fully understood, there are indications that morphine enhances inflammation at the 
injury site and exacerbates the secondary injury cascade. After an SCI the instantaneous 
flood of inflammatory cells to the injury site prevents injury damage from expanding 
indiscriminately along the cord (Faulkner et al. 2004). However, therapeutic strategies that 
prolong or augment the innate inflammatory response can delay injury resolution (Yao et 
al. 2014). Indeed, we have observed an increase in inflammatory cells at the injury site 
after a single i.t. dose of morphine (Aceves et al. 2019). We believe that this morphine-
induced inflammation is contributing to the surge in cell death that we see in our 




The communication between the opioid and the immune system has been 
extensively described in healthy and pathological models, including SCI. Opioid receptor 
activation can regulate the immune response by increasing the production of 
proinflammatory cytokines, but it can also promote apoptosis or proliferation of immune 
cells depending on factors like the type of opioid receptor being activated (Hutchinson et 
al. 2011). For instance, activation of KORs in spinal glia has been reported to increase 
their proliferation in vitro and in vivo (Bunn, Hanley, and Wilkin 1985; Xu et al. 2007; 
McLennan et al. 2008). Interestingly, we find that in our model activation of KORs is both 
sufficient and necessary to mediate the negative effects of morphine on motor recovery 
after an SCI (Aceves, Mathai, and Hook 2016; Aceves et al. 2017). It is possible that 
activation of opioid receptors, including KORs, is contributing to the elevation in the 
expression of immune cells after SCI.   
However, immune cells like microglia and macrophages are highly heterogenous 
in phenotype and function. Thus, it is just as important to assess the type of cells present 
at the site of injury as well as their number.  When microglia and macrophages get 
activated they are able adopt different phenotypes based on internal and external inputs 
from other cells.  Generally, activated microglia and macrophages are thought to polarize 
into either the classically (M1) or the alternatively (M2) activated phenotype. Classically 
activated or M1 microglia/macrophages were described in the literature first and result 
from the activation of resting microglia with interferon-  (IFN-) (Nathan et al. 1983). 
M1 microglia and macrophages mainly express pro-inflammatory elements including 




oxide (NO). Later, it was discovered that IL-4, which is mainly produced by Th2 cells, 
could induce a distinct or “alternative activation” of macrophages, giving rise to the M2 
phenotype (Stein et al. 1992). M2 macrophages seem to produce a different profile of 
molecules than M1 macrophages, including anti-inflammatory cytokines like IL-10 and 
growth factors that promote repair.  Following an injury, M1-like cells appear to be more 
predominant around the injury and help contain the damage, and as the injury progresses 
there is a shift towards M2-like microglia and macrophages. Treatments that accelerate 
this conversion, but do not suppress the initial M1 response seem to improve functional 
recovery and prevent further cell death (Francos-Quijorna et al. 2016; Yao et al. 2014).  
Based on this literature, the experiments described in this chapter evaluated the 
effect of repeated IV morphine administration after SCI on the expression of microglia 
and macrophages across different timepoints. In addition to quantifying the total numbers 
of microglia and macrophages expressed at the injury site, we used markers to identify 
M1 (CD86) and M2 (CD206) cell populations, as well a KOR antibody to quantify the 
expression of this receptor on the M1 and M2 subpopulations. The data presented here 
supports the premise that morphine administration increases the total number of microglia 
and macrophages following SCI which can potentially enhance the inflammatory 
response. The robust increase in KORs among these cells also aligns with our previous 
findings and supports a role for KOR in our model. More extensive research is needed to 
fully understand the functional effects of activating KORs and other opioid receptors on 










Figure 1. Timeline for Experiment 1. 
 
 
Experiment 1 was conducted according to Figure 1. Flow cytometry was used to 
compare the expression of activated microglia and macrophages after an SCI, at the site 
of the lesion, in rodents that received morphine vs. vehicle (0.9% saline). To evaluate 
changes in the temporal expression of the activated glia, morphine or saline were given 
for either 1, 3, or 7 days post injury and tissue was collected 24 hours after the last drug 
administration as described in Chapter II (General Methodology). This 2 (morphine or 
vehicle) x 3 (days of morphine administration) experimental design used 46 rats (n=5-6). 
To differentiate between the effect of surgery vs. drug treatment, two additional sham 
groups were added at the day 7 timepoint (n=6).  Sham subjects followed the same surgery 
and drug administration regimen as their contused counterparts, with half of the shams 




condition completed drug treatment and administration. Unfortunately, this tissue could 
not be processed successfully and had to be culled from the experiment, but the subjects 
were included in the behavior statistical analysis for a total n=10. All behavior analyses 
were conducted on subjects from the 7-day administration group to allow for a within-
subjects comparison from day 1 to day 7 scores. 
 
Effects of Morphine on Locomotor Recovery 
To assess the effects of morphine on recovery, locomotor behavior was scored 
daily using the BBB scale (Basso, Beattie, and Bresnahan 1995). Figure 2 shows mean 
converted BBB scores ( S.E.M) for the first seven days after surgery. A two-way repeated 
measures ANOVA showed a main effect of day post-surgery (F (6, 108) = 19.72, p < 
0.001) but not of treatment (F (1, 108) = 3.622, p = 0.07) on BBB scores. Locomotor 
scores on day one prior to drug treatment did not differ significantly between contused 
saline (1.70 ± 0.35) and contused morphine (1.65 ± 0.30) subjects. 
However, replicating previous studies, our analysis revealed a significant 
interaction between day post-surgery and treatment (F (6, 108) = 7.694, p < 0.001). Post 
hoc comparisons using the Holm-Šídák method indicated that saline-treated rats had 
significantly higher BBB scores than morphine-treated rats on days 6 and 7 post-surgery 
(t (126) = 2.739, p < 0.05; t (126) = 3.822, p < 0.05, respectively). Vehicle controls rats 
recovered to an average converted BBB score of 5.30 ± 0.89, while morphine-treated 




irrespective of treatment, had a converted BBB score of 12 (unconverted BBB score of 
21) throughout the seven-day post-surgery assessment period.  
 
 
Figure 2. Effects of intravenous morphine on locomotor recovery. Subjects scores were balanced across 
groups on day 1 post-injury. Morphine significantly undermined locomotor recovery in contused rats after 
7 days of IV administration. Results shown as Mean ± S.E.M. * p < 0.05, n=10.  
 
 
Effects of Morphine on Sensory Recovery 
Figure 3 illustrates the effects of morphine on sensory recovery for the first seven 
days following sham or contusion injury. Sensory recovery was evaluated by assessing 
thermal (tail-flick test) and mechanical reactivity (von Frey filaments) on the first and last 
day of treatment, immediately before and 30-min after the intravenous administration of 
morphine.  
 
























































Assessment of the analgesic efficacy of morphine.  
Morphine produced robust analgesia on thermal reactivity that persisted across the seven 
days of administration (Fig. 3A). Both sham and contused animals reached the maximum 
8-sec tail-flick latency after receiving morphine. A 3-way ANOVA revealed a significant 
main effect of drug treatment (F (1, 36) = 10.19, p < 0.001). There were no effects of 
surgery (F (1, 36) = 0.07, p = 0.80) or day of treatment (F (1, 36) = 3.41, p = 0.07) and no 
significant Surgery x Drug Treatment interactions. 
Similarly, morphine produced robust analgesia on the mechanical reactivity test at 
all timepoints. A 3-way ANOVA revealed a main effect of surgery (F (1, 36) = 8.95, p < 
0.05), a main effect of drug treatment (F (1, 36) = 44.62, p < 0.001), and a Surgery x Drug 
Treatment interaction (F (1, 36) = 8.95, p < 0.05) on the motor response to mechanical 
stimulation (Fig. 3B). Sham subjects showed higher sensitivity to tactile stimulation than 
contused rats across all days. Morphine administration also resulted in less vocal responses 
to mechanical stimulation across all testing days (Fig. 3C).  Again, there was a main effect 
of drug treatment (F (1, 36) = 10.79, p < 0.001), and no effect of surgery or significant 
interactions between drug treatment and surgery. We did not see evidence of tolerance to 
morphine developing across days. Analgesia on the thermal reactivity and mechanical 








Assessment of opioid-induced hyperalgesia 
Thermal and mechanical reactivity were also assessed prior to drug administration to 
monitor the development of opioid-induced hyperalgesia. There were no significant 
differences in tail-flick reactivity between conditions on day one post-injury. Across the 7 
days post-injury, however, there was a main effect of day of testing (F (1, 36) = 7.21, p < 
0.05) but no effect of surgery, drug treatment, or significant interactions (Fig. 3D). Post 
hoc comparisons using the Holm-Šídák method, revealed that latency to tail-flick was 
increased in morphine-treated sham subjects from day 1 to day 7 after injury (t (36) = 3.05, 
p < 0.05). Tail-flick latency did not change for the rest of the treatment groups across days. 
Conversely, evidence of opioid-induced hyperalgesia was observed on the 
mechanical reactivity test (Fig. 3, E-F). As with the assessment of tolerance, contused 
animals showed less motor reactivity to mechanical stimulation (F (1, 36) = 11.43, p < 
0.001).  However, the threshold for vocalizations in response to mechanical stimulation 
was significantly decreased in contused animals treated with morphine by day 7 (t (36) = 





Figure 3. Effects of morphine on thermal and tactile reactivity. Morphine produced robust analgesia on 
thermal (A) and tactile (B, C) reactivity. There was no reduction in the efficacy of morphine across days on 
either sensory test. Conversely, the development of hyperalgesia was observed by day seven on the tactile 
reactivity (E, F) test but not for thermal reactivity (D). Contused subjects treated with morphine displayed 
significantly lower thresholds for vocal (F), and a trend for reduction of motor (E), responses on the tactile 
reactivity test. Results shown as Mean ± S.E.M.  *p < 0.05, n=10.  
 
 
Exp. 1A: M1 Microglia and Macrophages 
Selective antibodies were used to label activated M1 microglia and macrophages 
in a heterogeneous mixture of dissociated primary cells extracted from the spinal cord 
tissue at the center of the lesion, and cell expression was quantified with flow cytometry. 
Figure 4 shows the general gating strategy used to identify cells of interest in the M1 set. 
First, cell debris was gated out using forward and side scatter. Then, viability was assessed 
using a zombie die (BioLegend, San Diego, CA). Dead cells internalize the fluorescent 
dye and give a positive signal, allowing for exclusion; all other cells were considered 


























































































































































To be considered positive (+), cell populations were selected using a gate that contained 
< 1% CD11b+ unstained cells. CD11b is expressed on a variety of immune cells, including 
neutrophils, monocytes, natural killer cells, and some lymphocytes (Kawai et al., 2005; 
Springer, 1990). Therefore, we quantified the total number of CD11b+ cells as an indirect 
measure of inflammation. To assess the effects on the peripheral versus resident immune 
response, a CD45 marker was used. CD11b+/CD45+ cells were selected and separated 
into discrete populations of high and low CD45 expression; we identified these cell 
populations as infiltrating macrophages (CD11b+/CD45High) and resident microglia 
(CD11b+/CD45Low) respectively, as previously done by others (Sedgwick et al. 1991; 
Ford et al. 1995; Badie and Schartner 2000; Martin et al. 2017). Next, a quadrant system 






Figure 4. Flow cytometry gating strategy for M1 Set. Forward and side scatter were used to remove debris 
(A). Dead cells internalize the Zombie dye and give a positive signal, allowing for further exclusion (B). 
Singlets were then selected using height and area of forward scatter (C). Microglia and macrophages were 
identified by selecting cells that were positive for CD11b (D). CD45 was then used to differentiate between 
infiltrating macrophages (CD45high) and resident microglia (CD45low) (E). A quadrant system was created 




Temporal Quantification of Microglia and Macrophages 
Figure 5 shows the quantification of CD11b+ cells, macrophages (CD45High), and 
microglia (CD45Low) estimated by flow cytometry analysis. A total of 100,000 events 
(total number of cells) were read per sample from a heterogenous mixture of spinal cord 
cells. The percentage of positive cells refers to the percentage of cells with a positive 
fluorescence signal in reference to the previous gate, not the total number of cells in the 
sample. As expected, the contusion injury significantly increases the number and 
percentage of CD11b+ cells, microglia, and macrophages at 7 days post injury, compared 
to sham surgery (F (1, 20) = 33.54, p < 0.001 and F (1, 20) = 27.82, p < 0.001, 
respectively), regardless of drug treatment. Moreover, an effect of morphine on cell 
numbers can be detected after just 3 days of morphine administration. At this timepoint 
there was a significant increase in the number of CD11b+ cells (t (8) = 6.67, p < 0.001), 
macrophages (t (8) = 7.03, p < 0.001), and microglia (t (8) = 2.79, p < 0.05) in the 
morphine-treated rats at the site of lesion compared to vehicle-treated animals (Fig. 5). 
There was no effect of treatment for 1 or 7 days on the number or percentage of CD11b+, 







Figure 5. Quantification of microglia and macrophages in M1 set using flow cytometry. The contusion 
injury significantly increases the number of CD11b total positive cells (A), percentage of CD11b positive 
cells (B), total number of macrophages (C), and total number of microglia (D) at the site of injury relative 
to a sham surgery. After 3 days of morphine administration, contused animals also had a significantly higher 
total number of CD11b positive cells (A), percentage of CD11b positive cells (B), total number of 
macrophages (C), and total number of microglia (D) compared with vehicle SCI controls. There was no 
significant effect of treatment with 1 or 7 days of morphine administration. Results shown as Mean ± S.E.M.  
*p < 0.05, n=5-6. 
 
 
Analysis and Quantification of M1 Microglia 
To further characterize microglia, we quantified the number of glia expressing the 
CD86 (M1 marker), the KOR, or both markers simultaneously as shown in Fig. 6.  The 
percentage of positive cells in Fig. 6 is presented in reference to the number of microglia 
(Fig. 5D) not the total number of cells in the sample. Our statistical analyses show that 
after 3 days of morphine administration there a significant decrease in the percentage of 
CD86+ cells (t (8) = 3.89, p < 0.001, Fig. 6A) but not in the overall number of CD86+ 





















































































































cells (t (8) = 0.85, p = 0.4226, Fig. 6D) as there were more microglia present at the site of 
lesion in morphine-treated rats at this timepoint. Conversely, morphine increases both the 
percentage of KOR+ microglia (Fig. 6B) and the total number of KOR+ microglia after 3 
days of administration (t (8) = 4.306, p < 0.001 and (t (8) = 7.41, p < 0.0001, respectively). 
In addition, the number of CD86+ microglia expressing KORs was also significantly 
increased after 3 days of morphine administration (t (8) = 1.92, p < 0.05) in comparison 
to saline-treated animals (Fig. 6F) but not the overall proportion (t (8) = 0.78, p = 0.46) 
(Fig. 6C). There was an additional main effect of surgery on the expression of KORs on 
day 7, with contused animals exhibiting significantly higher numbers of KOR+ microglia 
(F (1, 20) = 5.26, p < 0.05) compared to sham animals, irrespective of treatment (Fig. 6E). 








Figure 6. Quantification of microglia expressing CD86 (M1 marker) and KOR. Morphine significantly 
decreases the percentage of CD86+ microglia (6A) but not the overall number CD86+ microglia (6D) after 
3 days of I.V. administration. Conversely, there is a significant increase in both the percentage of KOR+ 
(6B) and total number of KOR+ (6E) microglia in contused subjects after 3 days of morphine administration. 
Morphine also increases the total number of CD86+ microglia expressing KORs (6F) after 3 days of 
administration. In addition, there is a main effect of surgery with contusion injury increasing the overall 




Analysis and Quantification of M1 Microglia 
As described for microglia, we quantified the number of macrophages expressing 
the CD86 (M1 marker), the KOR, or both markers simultaneously as shown in Fig. 7.  The 
percentage of positive cells in Fig. 7 is presented in reference to the number of 
macrophages (Fig. 5C) not the total number of cells in the sample. Our statistical analysis 
show that morphine has divergent effects on macrophages at different timepoints. 
Morphine administration significantly reduces the percentage of CD86+ (Fig. 7A) and the 
number of CD86+ (Fig. 7D) macrophages in contused subjects after 1 day of 








































































































































































administration (t (10) = 4.16, p < 0.001 and t (10) = 2.33, p < 0.05 respectively). The 
proportion of CD86+ macrophages remains significantly lower in morphine-treated rats 
by day 3 (t (8) = 5.037, p < 0.001, Fig. 7A). However, the overall number of CD86+ 
macrophages significantly increases by this same time point with morphine administration 
(t (8) = 2.658, p < 0.05, Fig. 7B) as a reflection of the overall increase in macrophages at 
the site of lesion. There is a main effect of surgery on CD86 expression on macrophages 
by day 7, with contused subjects exhibiting significantly higher numbers of CD86+ 
macrophages than shams (F (1, 20) = 16.07, p < 0.001, Fig. 7B).  
There were also converse effects of morphine on the expression of KOR in 
macrophages across days. After 1 day of morphine administration, there is a significant 
decrease in the percentage (Fig. 7B) but not the overall number (Fig. 7E) of KOR+ 
macrophages (t (10) = 4.156, p < 0.001, and t (10) =1.963, p =0.078, respectively). 
However, this trend is reversed by day 3 where there is a significant increase in the 
percentage (t (8) = 7.624, p < 0.0001) and overall number of KOR+ macrophages (t (8) = 
9.876, p < 0.0001) with morphine administration in contused subjects. As before, there is 
a main effect of surgery on the expression of KOR on macrophages observed on day 7 
with contused subjects exhibiting higher number of KOR+ macrophages (F (1, 20) = 9.55, 
p < 0.05) compared to sham subjects (Fig. 7E).  
This overall trend is also reflected when we evaluated CD86+ macrophages 
expressing KORs. After 1 day of morphine administration, there is a significant decrease 
in the percentage (Fig. 7D) and the overall number (Fig. 7F) of CD86+ macrophages 




Again, this effect is reversed by day 3 where there is a significant increase with morphine 
administration in the percentage (t (8) = 2.649, p < 0.05) and overall number of CD86+ 
macrophages expressing KORs (t (8) = 5.645, p < 0.0001) in contused subjects. As before, 
there is a main effect of surgery on the expression of KOR on CD86+ macrophages 
observed on day 7 with contused subjects exhibiting higher number CD86+ macrophages 
expressing KORs (F (1, 20) = 6.96, p < 0.05) compared to sham subjects (Fig. 7F).  
 
 
Figure 7. Quantification of macrophages expressing CD86 (M1 marker) and KOR. Morphine 
significantly decreases the percentage of CD86+ macrophages (A) but increases the overall number of 
CD86+ macrophages (D) after 3 days of administration. 3 days of morphine administration also increases 
the percentage (B) and total number (E) of KOR+ macrophages compared to vehicle-treated contused and 
sham subjects. Interestingly, 1 day of morphine administration decreases the percentage and number of 
CD86+ macrophages expressing KOR but 3 days of repeated morphine administration increases CD86+ 


















































































































































































Exp. 1B: M2 Microglia and Macrophages 
As with the M1 panel, selective antibodies were used to label activated M2 
microglia and macrophages in a heterogenous mixture of dissociated primary cells 
extracted from spinal cord tissue at the center of the lesion, and cell expression was 
quantified using flow cytometry. Figure 8 depicts the general gating strategy used to 
identify cells of interest in the M2 set. First, cell debris was gated out using forward and 
side scatter. Then, viability was assessed using a zombie die (BioLegend, San Diego, CA). 
However, as different CD11b antibodies were used for the M1 and M2 panels the gating 
strategy was lightly adjusted to accommodate for differences in autofluorescence baselines 
in different channels. Unstained cells display higher autofluorescence signaling in the 
FITC channel making it harder to differentiate between autofluorescence and the signal of 
interest. Therefore, in panel M2, to compensate for a higher level of auto-fluorescence in 
the FITC (CD11b) channel, we first created a gate that contained < 1% CD45+ unstained 
cells (Fig. 8D). The CD45 marker is expressed by T cells, B Cells, dendritic cells, natural 
killer cells, microglia and macrophages, and granulocytes. CD11b is expressed in only a 
subset of immune cells, including neutrophils, monocytes, and natural killer cells (Kawai 
et al., 2005; Springer, 1990). According to the literature, neutrophils are no longer detected 
at the site of injury 24-hours after the injury (Carlson et al. 1998), suggesting that CD11b+ 
cells in our sample are predominantly monocytes. Therefore, we next gated CD11b+ cells 
to select microglia and macrophages from the general CD45+ population (Fig. 8E). To 
assess the effects on the peripheral versus resident immune response, we used the CD45 




Schartner 2000; Martin et al. 2017). CD11b+/CD45+ cells were selected and separated 
into discrete populations of high and low CD45 expression; we identified these cell 
populations as infiltrating macrophages (CD11b+/CD45High) and resident microglia 
(CD11b+/CD45Low) respectively. Next, a quadrant system was created paring KOR vs. 







Figure 8. Flow cytometry gating strategy for M2 set. Forward and side scatter were used to select out 
debris (A). Dead cells internalize the Zombie dye and give a positive signal, allowing for exclusion (B). 
Singlets were selected using height and area of forward scatter (C). A gate for CD45+ cells was made to 
compensate for high auto-fluorescence in FITC channel (D). Microglia and macrophages were identified by 
selecting cells that were positive for CD11b (E). CD45 was then used to differentiate between infiltrating 
macrophages (CD45High) and resident microglia (CD45Low) (F). A quadrant system was created paring KOR 





Temporal Quantification of Microglia and Macrophages 
Figure 9 shows the quantification CD11b+ cells, macrophages (CD45High), and 
microglia (CD45Low) estimated by flow cytometry analysis. A total of 100,000 events 
(total number of cells) were read per sample from a heterogenous mixture of cells 
extracted from the spinal cord. The percentage of positive cells refers to the percentage of 
cells that gave of a positive fluorescence signal in reference to previous gate, not to the 
total number of cells in the sample. As expected, the contusion injury significantly 
increases the number and percentage of CD11b+ cells, microglia, and macrophages, at 7 
days post injury, compared to sham surgery (F (1, 20) = 7.080, p < 0.05 and F (1, 20) = 
7.392, p < 0.05), irrespective of drug treatment. Our statistical analyses revealed that 
morphine’s effects on cell numbers can be detected after just 3 days of morphine 
administration. At this timepoint there was a significant increase in the number of CD11b+ 
cells (t (8) = 4.768, p < 0.001), macrophages (t (8) = 4.691, p < 0.001), and microglia (t 
(8) = 3.492, p < 0.001) in the morphine-treated rats at the site of lesion compared to 
vehicle-treated animals, as well as the percentage of these cells (Fig. 9). There was no 
effect of treatment at 1 or 7 days on the number or percentage of CD11b+, macrophages, 





Figure 9. Quantification of microglia and macrophages in M2 set using flow cytometry. The contusion 
injury significantly increased the total number of CD11b+ cells (A), percentage of CD11b+ cells (B), total 
number of macrophages (C), and total number of microglia (D) at the site of injury in comparison to the 
sham surgery. After 3 days of morphine administration, contused animals also had a significantly higher 
total number of CD11b+ cells (A), percentage of CD11b+ cells (B), total number of macrophages (C), and 
total number of microglia (D) compared to vehicle controls. There was no significant effect of treatment 
after 1 or 7 days of morphine administration. Results shown as Mean ± S.E.M.  *p < 0.05, n=6. 
 
 
Analysis and Quantification of M2 Microglia 
To further characterize the microglia, we quantified the number of glia expressing the 
CD206 (M2 marker), KOR, or both markers simultaneously (Fig. 10). The percentage of 
positive cells shown in Fig. 10 is presented in reference to the number of microglia (Fig. 
9D) not to the total number of cells in the sample. After 3 days of morphine administration 
there was a significant increase in the percentage of CD206+ cells (t (8) = 2.936, p < 0.05, 
Fig. 10A) and in the overall number of CD206+ cells (t (8) = 3.456, p < 0.001, Fig. 10D) 
in morphine treated rats vs. saline controls. Conversely, after 1 day of administration 

















































































































saline-treated rats showed a modest but significantly higher number of CD206+ microglia 
(t (8) = 2.698, p < 0.05, Fig. 10D) compared to morphine-treated rats. Similarly, after 3 
days of morphine administration there was an increase in the total number of KOR+ 
microglia (t (8) = 3.132, p < 0.05, Fig. 10E) and a non-significant trend toward an increase 
in the percentage of KOR+ microglia (t (8) = 1.840, p = 0.0515, Fig. 10B) in morphine 
treated animals compared to vehicle. Additionally, after 3 days of administration, the 
percentage (Fig. 10C) and the total number of cells (Fig. 10F) of CD206+ microglia 
expressing KORs was increased in morphine-treated rats (t (8) = 3.125, p < 0.05 and t (8) 
= 3.905, p < 0.001, respectively). In contrast, after 1 day of treatment, saline-treated rats 
showed significantly higher numbers of CD206+ microglia expressing KORs (t (8) = 
2.659, p < 0.05, Fig. 10B) but not percentages (t (8) = 0.9876, p = 0.1723, Fig. 10B) 
compared to morphine-treated rats. There were no other significant main effects or 





Figure 10. Quantification of microglia expressing CD206 (M2 marker) and KOR. Morphine 
significantly increased the percentage of CD206+ microglia (A) and the total number of cells (D) after 3 
days of I.V. administration. After 3 days of administration there was also an increase in the total number of 
KOR+ microglia (E) in morphine treated animals. Similarly, 3 days of morphine administration increased 
the percentage (C) and total number (F) of CD206+ microglia expressing KOR as compared to vehicle 
contused rats. Conversely, after 1 day of administration, saline-treated animals showed higher number of 
CD206+ microglia (D) and CD206+ microglia expressing KOR (F) compared to morphine-treated rats. 
Results shown as Mean ± S.E.M.  *p < 0.05, n=6. 
 
 
Analysis and Quantification of M2 Macrophages 
To further characterize macrophages, we quantified the number of cells expressing the 
CD206 (M2 marker), KOR, or both markers simultaneously (Fig. 11). Our statistical 
analyses show that after 3 days of morphine administration there is a significant increase 
in the number of CD206+ macrophages (t (8) = 4.423, p < 0.001, Fig. 11D), as well as the 
overall proportion of CD206+ macrophages (t (8) = 2.059, p < 0.05, Fig. 11A) in morphine 
treated rats compared to controls. Additionally, 3 days of morphine administration 










































































































































































increased both the proportion (t (8) = 2.794, p < 0.05, Fig. 11B) and total number of KOR+ 
macrophages (t (8) = 4.926, p < 0.001, Fig. 11E). Similarly, there was an increase in the 
percentage of CD206+ macrophages expressing KOR (t (8) = 2.794, p < 0.05, Fig. 11B) 
and the overall number of CD206+ macrophages that were KOR+ (t (8) = 4.926, p < 0.001, 
Fig. 11E) in morphine-treated rats compared to vehicle. There was an additional main 
effect of surgery on day 7, where contused rats showed significantly higher numbers of 
CD206+ macrophages (F (1, 20) = 11.04, p < 0.001, Fig. 11D), number of KOR+ 
macrophages (F (1, 20) = 33.42, p < 0.0001, Fig. 11E), and number of CD206+ KOR+ 
macrophages (F (1, 20) = 15.70, p < 0.001, Fig. 116) compared to sham animals, but not 
in the overall proportion of those cells.  There were no additional significant main effects 








Figure 11. Quantification of macrophages expressing CD206 (M2 marker) and KOR. Morphine 
significantly increases the percentage (A) and total number (D) of CD206+ macrophages after 3 days of I.V. 
administration. Morphine also increases the percentage (B) and total number (E) of KOR+ macrophages. 
Similarly, 3 days of morphine administration increase both the percentage (C) and total number (F) of 
CD206+ macrophages expressing KOR compared to saline-treated rats. Results shown as Mean ± S.E.M.  




 In the experiments described in this chapter, I used flow cytometry to evaluate the 
effect of morphine on the expression of immune cells at different timepoints during the 
acute phase of injury. To gain a better understanding of changes in the temporal expression 
of these cells, I first quantified the number of microglia and macrophages present at the 
lesion site after 1, 3, and 7 days of morphine (or saline) administration in contused and 
sham subjects.  Commensurate with previous literature (David and Kroner 2011), we 
found that the contusion injury, regardless of drug treatment, promotes the recruitment of 












































































































































































activated microglia (CD11b+/CD45Low) and macrophages (CD11b+/CD45High) to the 
lesion relative to a sham surgery. Microglia and macrophage expression peaked between 
three and seven days after SCI, independent of treatment, also replicating previous reports 
(Popovich and Hickey 2001; Popovich, Wei, and Stokes 1997). In addition, the data 
presented here shows that morphine administration further increases the number of 
infiltrating macrophages and microglia at the site of injury in contused rats. Interestingly, 
in this experiment, the morphine-induced increase in immune cells was only significant 
after 3 days of administration. We did not see an increase in CD11b+ cells after 1 day of 
IV morphine administration as we have seen with a single dose of i.t. morphine (Aceves 
et al. 2019). The delay in recruitment of immune cells with systemic administration vs. 
the immediate immune response when morphine is delivered directly to the cord supports 
the idea that morphine indeed mediates the increase in expression of immune cells after 
SCI.   
In this experiment we cannot determine whether morphine promotes the 
recruitment of cells to the site of injury or whether it promotes the proliferation of immune 
cells already at the lesion, but others have suggested that opioid-immune interactions can 
trigger proliferation and apoptotic pathways (Tegeder and Geisslinger 2004). For instance, 
activation of KORs by morphine has been shown to increase the proliferation of microglia 
and macrophages in in vitro cultures (Bunn, Hanley, and Wilkin 1985; Xu et al. 2007; 
McLennan et al. 2008). It is possible that morphine’s activation of KORs on microglia and 




However, it is worth nothing that we have not assessed whether morphine increases the 
expression of other opioid receptor subtypes.  
The heterogeneity in phenotype and function of microglia and macrophages 
expands beyond differences in the type of ORs they express. In the literature these immune 
cells have been broadly sorted into an M1 pro-inflammatory or M2 anti-inflammatory 
phenotype. In SCI, M1-mediated functions have been determined to be neurotoxic while 
treatments that promote M2 macrophages at the injury report improvements in 
locomotion, increases in neuronal survival, and greater re-myelination (Bomstein et al. 
2003; Ma et al. 2015; Gensel et al. 2017; Jeong et al. 2017). To better understand the 
functional significance of the effect of morphine on the immune response, therefore, it is 
not sufficient to assess changes in the number of cells at the injury site, we must also 
differentiate the subtype of cells present at the lesion. To address this, I used the M1 
marker CD86 and the M2 marker CD206 to further characterize microglia and 
macrophages. Given that morphine increases the expression of pro-inflammatory 
cytokines around the lesion (Hook et al. 2011; Hu et al. 2018; Aceves et al. 2019), we had 
originally predicted that morphine would bias the polarization of microglia and 
macrophages toward an M1, and away from an M2, phenotype. However, the results from 
this study suggest that the complex mechanism through which morphine increases 
inflammation might include a shift in the M1:M2 ratio.  While I found that morphine did 
in fact increase the total number of M1 (CD86+) macrophages present at the lesion, it 
actually reduced the percentage of M1 microglia/macrophages in comparison to saline-




the overall proliferation of immune cells rather than a shift towards M1 polarization. More 
unexpected than this finding, was the robust increase in the percentage and the total 
number of M2 (CD206+) microglia and macrophages with morphine administration. 
However, short-term administration of morphine (3 days) has also been reported to reduce 
the number of M1 macrophages and increase M2 macrophages in a model of incision-
induced inflammation in mice (Godai et al. 2014).  
However, a mechanism by which morphine-activated M2 cells could promote 
neurotoxicity and inflammation in the first days following injury is through the release of 
iron. M2 macrophages phagocytose red blood cells from the hemorrhagic tissue. These 
red blood cells typically release iron, and after being phagocytized, higher iron levels can 
be detected on M2 cells as well. Damage to the membrane of these cells causes iron to 
leak out and promote neurotoxicity, undermine recovery, and increase the production of 
pro-inflammatory cytokines by M1 cells (Rathore et al. 2008). In the aforementioned 
experiments cell death induced by SCI was examined at 15 post-injury, however, extended 
administration of morphine – defined as 5 or more days of administration- induces 
apoptosis of microglia, macrophages, and neurons (Hu et al. 2002; Emeterio, Tramullas, 
and Hurle 2006; Hook et al. 2017). Morphine administration in vivo activates intrinsic and 
extrinsic apoptotic signals to induce cell death (Boronat, Garcia-Fuster, and Garcia-Sevilla 
2001; Schwarz, Smith, and Bilbo 2013). The accelerated death of glia is then likely to 
increase the release of neurotoxic elements, especially after SCI when monocytes and 




The results from the present study also support the notion that morphine becomes 
excitotoxic after 7 days of repeated administration and that it might disproportionally 
affect M2 cells. Our statistical analyses show that in saline-treated rats the number of 
activated microglia and macrophages is reduced by half from day 3 to day 7 after injury. 
This decrease is more pronounced in M2 cells compared to M1s, especially in morphine-
treated rats where the number of M2 cells is substantially reduced by day 7 compared to 
their saline counterparts (Fig. 10D and 11D). Additionally, our data shows that the timing 
of M2 cell loss overlaps with the first signs of mechanical hypersensitivity observed in 
rats. In a model of incision-induced inflammation, early morphine-induced increase in 
number of M2 macrophages are thought to mediate the analgesic effects of morphine and 
to alleviate post-incisional pain in mice (Godai et al. 2014). Similarly, perineural 
transplantation of M2 macrophages 14 days following a chronic constriction injury also 
reduced mechanical hypersensitivity in rodents seemingly through the release of opioid 
peptides like Met-enkephalin, dynorphin A (1–17), and β-endorphin (Pannell et al. 2016). 
Thus, it is possible that loss of M2 macrophages after extended morphine administration 
is a contributing factor in the development of paradoxical pain induced by morphine.  
In summary, we found that morphine increases the expression of immune cells at 
the injury site but, intriguingly, the most robust increases were seen in the M2 subtypes. 
Interestingly, the expression of KORs was similarly increased across both M1 and M2 
microglia/macrophages. Importantly, the distinction between the two phenotypes in-vivo 
is not as clear-cut as it sometimes appears to be in the literature, especially under 




of opioid receptor expression on the M1 and M2 subtypes of microglia and macrophages 
after SCI with morphine administration.  Unfortunately, no studies have looked at 
functional effects of the activation of KORs (and other ORs) on these subtypes of glia or 
how that might affect their phenotype. We hypothesize that morphine does not only 
increase the number of microglia and macrophages present at the site of injury but that it 





CHAPTER IV  
ASSESSMENT OF THE FUNCTIONAL EFFECTS OF MORPHINE ACTIVATION 
OF OPIOID RECEPTORS 
 
Introduction 
 In the previous chapter, we presented data showing that morphine administration 
after SCI changes the expression of activated microglia and macrophages at the lesion site. 
Interestingly, at different timepoints, our results support both of the seemingly 
contradictory reports in the literature on whether opioid activation of immune cells induces 
proliferation or apoptosis. While we saw a robust increase in the number of activated 
microglia and macrophages after 3 days of morphine administration, by day 7 there were 
no differences in immune cell numbers between saline- and morphine-treated rats. Indeed, 
previous work from our laboratory and others, shows that chronic (more than 5 days), but 
not acute, morphine administration induces apoptosis of neurons, astrocytes, and immune 
cells (Emeterio, Tramullas, and Hurle 2006; Hook et al. 2017). Opioid-immune 
interactions can significantly change the inflammatory response after SCI and could be 
the mechanism underlying the morphine-induced cell death that is potentiated sometime 
between day 3 and day 7 post-injury.  
In support of an interaction between the immune and the opioid system mediating 
the effects of morphine in our model, we observed an increase in KOR expression on 
microglia and macrophages after 3 days of morphine administration. These findings are 




morphine-induced attenuation of function. However, while we originally hypothesized 
that the expression of KORs on microglia and macrophages mediates the negative effects 
of morphine, a number of alternative opioid-immune activation patterns should also be 
considered. For instance, morphine will simultaneously bind to KORs in glia as well as to 
other ORs expressed by these cells to enhance the immune response. Therefore, the 
immunomodulatory effects of morphine could be mediated through the combined 
activation of classic and non-classic opioid receptors. In fact, a number of papers have 
suggested that the apoptotic effects of morphine are mediated through the activation of 
TLRs rather than the classic opioid receptors (Schwarz, Hutchinson, and Bilbo 2011; 
Schwarz, Smith, and Bilbo 2013; Shafie et al. 2015). While KORs appear to be 
upregulated on microglia and macrophages after morphine and SCI, we have not assessed 
whether other receptor subtypes are also affected or whether activation of KORs on these 
cells are critical to the morphine-induced attenuation of function. 
Irrespective of the OR subtype(s) activated, however, we know that the negative 
effects of morphine on locomotor recovery can be blocked by preventing glia activation, 
strongly suggesting a glia-mediated mechanism. Therefore, in this chapter, we assessed 
whether morphine administration changes the immune function of microglia and 
macrophages after SCI. All ORs are part of the G-protein couple receptor (GPCR) family 
and their activation triggers a complex chain of signaling events happening in parallel, 
each with its own functional implications. Briefly, upon activation of a GPCR the  
subunit of the G protein dissociates from the G subunit and each subunit mediates 




arrestin is recruited by G protein coupled receptor kinases (GRKs) to bind and deactivate 
the GPCRs. Arrestin typically targets the receptor for internalization and induces -
arrestin signaling, a G-protein independent signaling pathway. The -arrestin pathway in 
particular has been reported to mediate inflammation, opioid tolerance, apoptosis, and 
gene-transcription of peptides like Dynorphin through the recruitment of components of 
the MAPK family including ERK 1/2, p38, and c-Jun-N-terminal kinase 3 (JNK3). 
Accordingly, activation of classic opioid receptors (ORs) (Kappa, Mu, and Delta) 
on glia cells has been shown to induce p38 MAPK resulting in increased inflammation 
(Tibbles and Woodgett 1999) and increased production of proinflammatory cytokines like 
IL-B, IL-6, TNF-a, and nitric oxide synthase (Ashwell 2006). OR activation also induces 
ERK 1/2 which is an upstream kinase responsible for CREB upregulation of dynorphin 
gene expression (Carlezon, Duman, and Nestler 2005). Dynorphin A, an endogenous 
ligand of KOR, is particularly important in SCI research because is naturally upregulated 
during nerve injury in response to pain signaling. However, whereas neuronal production 
of Dynorphin promotes analgesia, glia-mediated production of Dynorphin A contributes 
to the development of allodynia (Xu et al. 2004; Zhu et al. 2006). Therefore, it is possible 
that morphine might not exert its negative effects through the activation of KORs on glia, 
but through an increase in the production of neurotoxic dynorphin by glia cells. At elevated 
levels, dynorphin A induces neurotoxicity, causes motor dysfunction in uninjured rats, 
exacerbates the injury in SCI rats, and contributes to the development of allodynia and 




To address this, the experiments in this chapter assessed whether morphine-
activation of microglia and macrophages after SCI engages signaling pathways associated 
with the production of pro-inflammatory cytokines and neurotoxicity. The literature 
strongly suggests that upon OR activation the -arrestin pathway becomes a key mediator 
of inflammation and apoptotic signals. Therefore, we used western blot analyses to 
quantify changes in protein expression of -arrestin and its downstream signaling proteins 
ERK 1/2 and p38 MAPK, as well as dynorphin and pro-dynorphin which are regulated 
through this signaling pathway. We first assessed protein expression on CD11b+ cells 
(microglia and macrophages) at the site of injury, 24-hours after the last drug 
administration (Exp. 2A). Our results suggest that, contrary to our initial hypothesis, after 
7 days of repeated morphine administration the expression of certain proteins in the -
arrestin pathway are reduced. However, the 24-hour washout period implemented in Exp. 
2A is longer than the half-life of morphine in rats. Therefore, these effects are more likely 
due to long-lasting changes induced by morphine administration rather than due to 
morphine actively inducing OR regulation of downstream signaling processes. To better 
understand the acute effects of morphine-mediated activation of ORs on downstream 
signaling pathways, in Exp. 2B we collected the spinal tissue 30-minutes after the last 
drug administration on day 3 post-injury.  As expected, our analyses at this earlier 
timepoint revealed that morphine significantly increases the expression of -arrestin 






Methods and Results 
Experimental design 
 
Figure 12. Timeline for Experiment 2. 
 
 
Experiment 2 was conducted according to the timeline depicted in Figure 12. 
Details on the experimental procedures are provided in Chapter II. Western blot analysis 
was used as a semi-quantitative assay to estimate the expression of proteins pertaining to 
the -arrestin signaling pathways initiated by OR activation in rats that received morphine 
versus vehicle (0.9% saline) administration. To evaluate changes in protein expression at 
different timepoints following an SCI injury, morphine or vehicle were given 
intravenously for either 1, 3, or 7 days post injury and tissue was collected 24 hours after 
the last administration as described in Chapter II (General Methodology). After 
dissociating primary cells from the injured spinal cord, microglia and macrophages were 
separated from a heterogenous mixture of cells using magnetic-activated cell sorting 
(MACS) in combination with anti-CD11b magnetic beads. The protein extracted from the 
CD11b+ effluent was quantified and used for western blot analysis. Samples from 2 




protein to perform the analysis. This 2 (morphine or vehicle) x 3 (days of morphine 
administration) experimental design used 72 rats (n = 6). To differentiate between the 
effect of surgery versus drug treatment, two additional sham groups were added at the day 
3 timepoint (n = 6). Sham subjects followed the same surgery and drug administration 
regimen as their contused counterparts, with half of the shams receiving morphine and 
half receiving saline.   
The half-life of morphine in rodents is approximately 41 min (Zheng, McErlane, 
and Ong 1998), thus morphine is washed out of the system at the 24-hour post-
administration tissue collection timepoint. Therefore, to evaluate the effects of morphine 
while the drug was still present in the system we included two additional group of rats that 
received intravenous morphine (or vehicle) administration for 3 days and the tissue was 
collected 30-minutes after the last administration (n = 6).  
 
Effects of Morphine on Locomotor Recovery  
To assess the effects of morphine on recovery, locomotor behavior was scored 
daily using the BBB scale. Figure 13 shows mean converted BBB scores ( S.E.M) for 
the 7-day treatment group. While samples from 2 subjects belonging to the same treatment 
group were pooled together to obtain sufficient protein to perform the analysis of CD11b+ 
protein, all behavioral analyses were done using the total number of rats in the study 
(n=12). A two-way repeated measures ANOVA showed main effects of day post-surgery 
and drug treatment (F (6, 132) = 36.78, p < 0.001 and F (1, 22) = 6.279, p < 0.05, 




significantly between contused saline (1.83 ± 0.37) and contused morphine (1.58 ± 0.44) 
subjects. 
Replicating previous studies, our analysis revealed a significant interaction 
between Day post-surgery x Treatment (F (6, 132) = 11.87, p < 0.001). Post hoc 
comparisons using the Holm-Šídák method indicated that saline-treated rats had 
significantly higher BBB scores than morphine-treated rats on days 6 and 7 post-surgery 
(t (154) = 4.619, p < 0.001 and t (154) = 4.302, p < 0.001, respectively). Vehicle controls 
rats recovered to an average converted BBB score of 5.33 ± 0.83, while morphine-treated 
subjects recovered to an average converted BBB score of 3.29 ± 0.84. All sham rats, 
irrespective of treatment, had a converted BBB score of 12 (unconverted BBB score of 
21) throughout the post-surgery assessment period.  
 
 
Figure 13. Effects of intravenous morphine on locomotor recovery. Scores from the 7-day group subjects 
were balanced on day one post-injury. Morphine significantly undermined locomotor recovery by day 7 
post-surgery. Results shown as Mean ± S.E.M. * p < 0.05, n=10. 
 























































































































Effects of Morphine on Sensory Recovery 
Figure 14 illustrates the effects of morphine or saline on sensory recovery for the 
7-day group contused subjects. Sensory recovery was evaluated by assessing thermal (tail-
flick test) and mechanical reactivity (von Frey filaments) on the first and last day of 
treatment, immediately before (hyperalgesia) and 30-min after (analgesic efficacy) the 
intravenous administration of morphine.  
 
Assessment of the Analgesic Efficacy of Morphine 
Morphine produced robust analgesia on thermal reactivity that persisted across the seven 
days of administration (Fig. 14A). All animals reached the maximum 8-sec tail-flick 
latency after receiving morphine. A 2-way ANOVA revealed a significant main effect of 
drug treatment (F (1, 22) = 251.5, p < 0.001) and a main effect of day post-surgery (F (1, 
22) = 8.62, p < 0.01) on tail-flick latency. There was also a significant interaction between 
Day x Treatment (F (1, 22) = 4.59, p < 0.05). 
Similarly, morphine produced robust analgesia on the mechanical reactivity test at 
all timepoints. A 2-way ANOVA revealed a main effect of day post-surgery (F (1, 22) = 
32.92, p < 0.001), a main effect of drug treatment (F (1, 22) = 40.52, p < 0.001), and a 
Day x Treatment interaction (F (1, 22) = 32.52, p < 0.001) on the motor response to 
mechanical stimulation (Fig 14B). Morphine administration also resulted in less vocal 
responses to mechanical stimulation across all testing days (Fig. 14C).  Again, our 




a main effect of drug treatment (F (1, 22) = 6.98, p < 0.05), and a Day x Treatment 
interaction (F (1, 22) = 6.49, p < 0.05). While the saline-treated rats decreased their vocal 
reactivity thresholds across the 7 days post-injury, we did not see evidence of tolerance to 
morphine developing across days. Analgesia on the thermal reactivity and mechanical 
stimulation tests persisted across the 7 days of administration (Fig. 14, A-C).  
 
Assessment of opioid-induced hyperalgesia 
Thermal and mechanical reactivity were also assessed prior to drug administration to 
monitor the development of opioid-induced hyperalgesia. There were no significant 
differences in tail-flick reactivity between conditions on day 1 or day 7 post-injury. There 
were no main effects of day post-surgery, drug treatment, or significant interactions (Fig. 
14D) across days.  
Conversely, evidence of opioid-induced hyperalgesia was observed on the 
mechanical reactivity test (Fig. 14, E and F). There was a main effect of day post-surgery 
(F (1, 22) = 7.37, p < 0.05) on motor reactivity, but no effect of drug treatment or 
significant interactions. Post hoc comparisons using the Holm-Šídák method indicated that 
the motor reactivity thresholds were significantly lowered in morphine-treated subjects 
from day 1 to day 7 (t (22) = 2.82, p < 0.05) but not in saline-treated rats. Similarly, there 
was a main effect of day post-surgery (F (1, 22) = 6.04, p < 0.05) and a main effect of 
treatment (F (1, 22) = 5.75, p < 0.05) on vocalizations to tactile stimulation. Post hoc 




stimulation was significantly decreased from day 1 to day 7 in contused animals treated 
with morphine (t (22) = 2.605, p < 0.05), relative to saline, as shown in Fig. 14F.  
 
 
Figure 14. Effects of morphine on thermal and tactile reactivity. Morphine produced robust analgesia 
on thermal (A) and tactile (B, C) reactivity. There was no reduction in the efficacy of morphine across days 
on either sensory test. Conversely, the development of hyperalgesia was observed by day 7 on the tactile 
reactivity (E, F) test but not for thermal reactivity (D). Contused subjects treated with morphine displayed 
significantly lower thresholds for vocal (F), and a trend for a reduction of motor (E) responses on the tactile 
reactivity test. Results shown as Mean ± S.E.M.  *p < 0.05, n=12. 
 
 
Exp. 2A: Protein Analysis of CD11b+ cells 24-hours post-administration 
We used western blot analysis to quantify the expression of proteins in the B-arrestin 
pathway. Briefly, PVDF membranes were stained with REVERT Total Protein Stain (LI-
COR Biosciences, Lincoln, NE, USA) (Fig. 15) as an internal loading control to enable 


























































































































































software to calculate a Lane Normalization Factor (Lane Normalization Factor = Internal 
Loading Control Signal for Lane / Highest Internal Loading Control Signal). Then 
selective antibodies were used to probe PVDF membranes for proteins of interest in the 
-arrestin inflammatory pathway (-arrestin, ERK 1/2, and p38) and downstream 
neurotoxic molecules (dynorphin and its precursor pro-dynorphin). Fluorescence signal 
values for each protein band were normalized in relation their own internal loading control 
(Normalized Signal = Target Band Signal / Lane Normalization Factor). Additionally, 5-
cm of uninjured spinal cord from two sham-saline rats were collected and the extracted 
protein was used as an inter-membrane control by loading the protein sample onto the first 
two lanes of every gel. Therefore, this protein ratio (Protein ratio = Normalized Signal / 








Figure 15. REVERT Total protein stain as internal control. Protein collected from subjects treated for 3 
days with i.v. drug administration. Samples taken 24-hours after the last drug dose and processed with LI-
COR system. Loading control: protein extracted from whole spinal cord tissue from sham subjects treated 
with saline (lanes 2-3). 
 
 
Quantification of -arrestin Signaling Pathway Proteins 
Figure 16 shows the quantification of proteins relevant to the -arrestin pathway 
in CD11b+ cells estimated by western blot analysis, including -arrestin and downstream 
signaling molecules p38 MAPK and ERK 1/2.  Expression of the protein of interest was 
first normalized to its own loading control and then to a standard loading control used 
across gels (see previous section for description). There was a main effect of surgery 




protein compared to the sham surgery (F (1, 20) = 4.85, p < 0.05), irrespective of drug 
treatment (Fig. 16A). However, there were no main effects of drug treatment across days.  
Similarly, our statistical analyses showed a main effect of surgery on the 
quantification of p38 MAPK on day 3. The contusion injury significantly increasing the 
expression of p38 MAPK in CD11b+ cells compared to the sham surgery (F (1, 20) = 
4.57, p < 0.05) irrespective of treatment (Fig. 16B). Additionally, after 7 days of drug 
administration there was a significant decrease in the expression of p38 MAPK in 
morphine-treated rats (t (10) = 2.465, p < 0.05) as compared to saline-treated animals. 
There were no significant effects of treatment on days 1 or 3 of drug-administration on 
p38 MAPK expression. We also analyzed the expression of ERK 1/2, which can be 
activated through the -arrestin or G-protein signaling pathways. While there was a trend 
toward an increase in protein expression of ERK 1 and ERK 2 on day 3 in morphine-
treated rats (t (10) = 1.32, p = 0.10 and t (10) = 1.06, p = 0.16, respectively), there were 





Figure 16. Quantification of -arrestin pathway proteins in CD11b+ cells 24-hours after morphine 
administration. The contusion injury significantly increased the expression of -arrestin (A) and p38 
MAPK (B) on day 3. Additionally, morphine significantly decreases the expression of p38 MAPK by day 7 
compared to saline-treated rats (B). Tissue used for western blot analysis was collected 24-hours after the 




Figure 17. Western blot gels of -arrestin, p38 MAPK, and ERK 1/2 imaged with LI-COR. Protein 
collected from subjects that received 3 days of consecutive i.v. drug treatment. Samples taken 24-hours after 
the last drug dose and processed with LI-COR system. Loading control: protein extracted from whole spinal 
cord tissue from sham subjects treated with saline (lanes 2-3). REVERT Total protein stain used as internal 
control. 





























































































































































































Quantification of Opioid Peptide Dynorphin 
Figure 18 shows the quantification of the opioid peptide dynorphin and its 
precursor pro-dynorphin in CD11b+ cells estimated by western blot analysis. 
Transcription of dynorphin is regulated by the -arrestin pathway, therefore we quantified 
the expression of dynorphin and its precursor pro-dynorphin as a measure of -arrestin 
activity. Expression of each protein of interest was first normalized to its own loading 
control and then to a standard loading control used across gels (see previous section for 
description). There were no significant effects of surgery on the expression of pro-
dynorphin or dynorphin. However, similar to p38 MAPK levels, there was a significant 
decrease in the expression of pro-dynorphin on day 7 in morphine-treated subjects (t (10) 
= 2.502, p < 0.05) compared to saline-treated rats (Fig. 18A). There were no additional 
effects of treatment for days 1 or 3. Our statistical analyses did not show main effects of 
treatment for dynorphin on any of our test days (Fig. 18B).  
 
 
Figure 18. Quantification of dynorphin and its precursor pro-dynorphin. Morphine administration 
significantly decreases the expression of pro-dynorphin compared to saline-treated subjects by day 7 (A). 
Tissue used for western blot analysis was collected 24-hours after the last drug-administration. Results 
shown as Mean ± S.E.M.  *p < 0.05, n=6. 




































































































Figure 19. Western blot gels of dynorphin and pro-dynorphin imaged with LI-COR. Protein collected 
from subjects that received 3 days of consecutive i.v. drug treatment. Samples taken 24-hours after the last 
drug dose and processed with LI-COR system. Loading control: protein extracted from whole spinal cord 




Exp. 2B: Protein Analysis of CD11b+ Cells 30-Minutes Post-Administration 
In experiment 2B, contused rats were given morphine or vehicle for 3 days and 
spinal cord tissue was collected 30 minutes after the last drug administration. This earlier 
collection timepoint allowed us to better understand the signaling pathways initiated by 
the binding of morphine to opioid receptors while morphine is still active in the system of 
our subjects. Tissue collection, protein extraction, and western blot analysis were done as 
described in experiment 2A. As before, fluorescence signal values of the protein of interest 
were normalized in relation to their own internal loading control (Normalized Signal = 
Target Band Signal / Lane Normalization Factor). Protein extracted from CD11b+ cells 
from sham-saline subjects was used as an inter-membrane control by loading this protein 
sample onto the first two lanes of every gel. The normalized signal value was then 




Normalized Signal / Average of Normalized Signal for Controls) and this value was used 
for statistical analysis and reports. 
 
Quantification of -arrestin Signaling Pathway Proteins 
 As in experiment 2A, we used western blot analysis to quantify -arrestin, p38 
MAPK, and ERK 1/2 in CD11b+ cells with and without morphine administration (Fig. 
20). Supporting our hypothesis, quantification of signaling proteins at this earlier time 
point revealed that morphine-treated subjects showed a significant increase in -arrestin 
(t (10) = 2.49, p < 0.05) and ERK 1 (t (10) = 2.10, p < 0.05) compared to their saline-
treated counterparts (Fig. 20, A and C). Although there was a trend toward an increase in 
p38 MAPK and ERK 2 expression in morphine-treated subjects these effects were not 







Figure 20. Quantification of -arrestin pathway proteins in CD11b+ cells 30-minutes after drug 
administration. Morphine administration significantly increases the expression of -arrestin (A) and ERK 




Figure 21. Western blot gels of -arrestin, p38 MAPK, and ERK 1/2 imaged with LI-COR. Protein 
collected from subjects that received 3 days of consecutive i.v. drug treatment. Samples taken 30-minutes 
after the last drug dose and processed with LI-COR system. Loading control: protein extracted from whole 
























































































































































































Quantification of Opioid Peptide Dynorphin 
Figure 22 shows the quantification of the opioid peptide dynorphin and its 
precursor pro-dynorphin in CD11b+ cells 30 minutes after the last drug administration as 
estimated by western blot analysis. Quantification of protein at this earlier timepoint again 
revealed that morphine administration significantly increases the expression of pro-
dynorphin (t (10) = 2.014, p < 0.05) and dynorphin (t (10) = 2.715, p < 0.05) as compared 
to saline-treated subjects (Fig. 22, A and B). 
 
 
Figure 22. Quantification of dynorphin and its precursor pro-dynorphin in CD11b+ cells 30-minutes 
after drug administration. Morphine administration significantly increases the expression of pro-
dynorphin (A) and dynorphin (B) in contused rats compared to their saline-treated counterparts. Results 



































































































Figure 23. Western blot gels example of pro-dynorphin and dynorphin imaged with LI-COR. Protein 
collected from subjects that received 3 days of consecutive i.v. drug treatment. Samples taken 24-hours after 
the last drug dose and processed with LI-COR system. Loading control: protein extracted from whole spinal 





 In this chapter, I used western blot analysis to estimate changes in the 
concentration of proteins downstream of the inflammatory -arrestin pathway, initiated 
by OR activation. To gain a better understanding of any long-term changes versus active 
effects of morphine stimulation, we collected spinal tissue either 24 hours after the last 
drug administration (when morphine is washed out of the system) or 30-min following 
morphine administration. As expected, we observed an increase in the expression of 
proteins in the -arrestin pathway of contused rats that received IV morphine for 3 
consecutive days when we collected the spinal tissue 30-minutes after the last 
administration.  However, we do not see this effect when we delay tissue collection by 24-
hours post-administration, suggesting that our effects at this timepoint are due to active 




Of interest, our data shows that morphine activation increases the expression of 
dynorphin and pro-dynorphin in CD11b+ cells (Fig. 7). Dynorphin is endogenously 
produced under normal physiological conditions but is its expression increases after an 
SCI and correlates with injury severity (Przewlocki, Shearman, and Herz 1983; Cox et al. 
1985; Faden et al. 1985; Faden 1990). After SCI, low neurophysiological levels of 
dynorphin mediate analgesia through the activation of KORs in neurons (Mika, Obara, 
and Przewlocka 2011). However, with supraphysiological concentrations of, or prolonged 
exposure to, dynorphin becomes neurotoxic, induces paraplegia in normal rats when 
administered intrathecally, increases SCI dysfunction in rodents, and mediates 
hyperalgesia (Long et al. 1988; Hu et al. 1996; Faden 1990; Laughlin et al. 2000; Adjan 
et al. 2007; Mika et al. 2010). The neurotoxic effects of dynorphin excitation are mediated 
through a combination of opioid and non-opioid mechanisms in both glia and neurons 
(Hauser et al. 2005). However, evidence shows that glia-mediated, but not neuronal-
mediated, production of dynorphin may have negative consequences for recovery after 
SCI and pain development (Xu et al. 2004; Zhu et al. 2006; Mika et al. 2010). In a rodent 
model of neuropathic pain, pre-treatment with minocycline before chronic constriction of 
the sciatic nerve dampens microglia and macrophage activation, reduces prodynorphin 
mRNA levels, and prevents hyperalgesia development (Mika et al. 2010). Therefore, 
while we had originally hypothesized that the negative effects of morphine were mediated 
through the activation of KORs on microglia and macrophages, it is possible that 
morphine’s neurotoxic effects are instead due to the increase of microglial production of 




signaling that results in upregulation of pro-dynorphin (Carlezon, Duman, and Nestler 
2005). Indeed, our data shows that both -arrestin and ERK1 protein levels are elevated 
30-minutes after morphine administration similar to dynorphin and pro-dynorphin.  
 Unexpectedly, when we quantified protein levels 24-hours post administration on 
the 7-day morphine group, we saw a depletion of pro-dynorphin levels but not dynorphin 
compared to saline-treated contused animals. So far, we have focused on glia-to-neuron 
communication through the release of dynorphin and cytokines. However, communication 
between these two cells types is bidirectional, as they are speculated to engage in a 
feedforward loop. Neuron-to-glia signals maintain the activation of microglia loop. In our 
model we have seen dramatic loss of neurons after 7 days of morphine administration 
(Hook et al. 2017). It is possible that neuronal death at this timepoint disrupts this glia-
neuronal loop, and no longer signals glia to engage in the production of pro-dynorphin. 
Alternatively, the decrease in pro-dynorphin may be related to the timing of tissue 
extraction. It is possible that at Day 7, as found for Day 3, prodynorphin levels are 
increased while morphine is in the system and the decrease at 24 hours reflects depletion 
of this precursor protein with the synthesis and release of dynorphin. 
Additionally, our data shows a trend towards an increase in p38 MAPK protein at 
the 30-min collection timepoint, although this effect did not reach significance. Morphine 
elevation of p38 in microglia has been shown to induce apoptosis, antinociceptive 
tolerance, and an increase in pro-inflammatory cytokines including NF-, IL-6, and 
TNF- (Cui et al. 2006; Sawaya et al. 2009; Wang et al. 2009; Xie et al. 2010). Puzzlingly, 




sham subjects, we also observed a decrease in p38 levels in contused rats after 7 days of 
morphine administration compared to saline-treated animals. In spinal microglia, elevated 
p38 MAPK levels have also been linked to morphine tolerance and pain sensitivity (Cui 
et al. 2008). In rats, p38 elevation in microglia is observed in rats that develop tolerance 
to i.t. morphine after 7 days of administration (Cui et al. 2006). However, in our model, 
we choose to use an escalating dose of morphine to prevent morphine tolerance, as 
evidenced by our thermal and sensory reactivity tests (Fig.14). Further research is needed 






CHAPTER V  
ASSESSMENT OF MORPHINE ON THE PHAGOCYTIC FUNCTION OF 
MICROGLIA AND MACROPHAGES 
 
Introduction 
 The previous experiments show that morphine increases the expression of 
microglia and macrophages at the lesion site in the days following the injury, and that it 
may simultaneously induce cell death by increasing the expression, and presumably 
release, of dynorphin from these cells. Irrespective of whether morphine-induced 
production of dynorphin is the main mechanism underlying cell death in our SCI model, 
however, we have previously reported a dramatic elevation in neuronal death with 
extended IV morphine administration (Hook et al. 2017). These findings underscore the 
importance of the immune system after SCI to engage phagocytic microglia and 
macrophages to remove injury debris and damaged cells. Thus, it is equally important to 
characterize the phagocytic function of these cells to better understand the full effect of 
morphine on the immune response to SCI.  
Indeed, previous studies have shown that morphine decreases the phagocytic 
function of macrophages in vitro and in vivo. Rojavin et al. (1993) showed that morphine, 
delivered through a subcutaneous pellet, reduced the percentage of macrophages that 
ingested yeast as well as the average number of yeasts phagocytized per macrophage. The 
authors cautioned that their effects were modest and became less pronounced with 




phagocytosis assay (Rojavin et al. 1993). Nonetheless, similar decreases in phagocytic 
function after morphine administration have also been reported by others (Bosshart 2010). 
Importantly, the interference of morphine with phagocytic function has also been observed 
in rodent models of SCI where microglial phagocytosis was reduced (Hu et al. 2018). We 
know that treatments that delay axon and cell debris cleanup prevent axonal regeneration, 
increase neuronal death, delay injury resolution, and enhance inflammation after SCI 
(Perry, Brown, and Gordon 1987; Rapalino et al. 1998; Imai et al. 2008). In fact, it has 
been hypothesized that one reason axonal regeneration happens more frequently after a 
peripheral nervous injury is due to the rapid response by phagocytic macrophages that 
begin clearing up debris compared to a central nervous injury where macrophage 
infiltration is delayed (Perry, Brown, and Gordon 1987). For instance, in mice, chemical 
demyelination produces similar levels of myelin debris than a moderate contusion but it 
induces faster infiltration of bone-derived macrophages. The delay in macrophage 
infiltration after a contusion injury is thought to be responsible for the persistence of 
myelin debris around the injury which in turn releases inhibitory signals that prevent 
remyelination in SCI mice (Imai et al. 2008). By decreasing macrophage phagocytosis 
morphine may also undermine functional recovery after SCI. 
Other studies, however, have challenged the idea that morphine reduces 
phagocytosis and instead have found that morphine administration stimulates human 
microglial cells phagocytic function in vitro (Peterson et al. 1995; Lipovsky et al. 1998). 
In both of these studies human fetal microglia pre-treated with morphine (for 18 - 24 




authors propose that their findings might differ from previous literature due to 
physiological differences between human microglia and other animal models since most 
phagocytosis studies are conducted in rodents or swine. Alternatively, Lazaro et al. (2000) 
proposed that the contradictory findings could be due to variations in the dose and length 
of administration of morphine. In their own study, acute administration (30 mins) of 
morphine decreased macrophage phagocytosis. However, after extended administration 
(8 hours) macrophages seemed to develop tolerance to morphine and to require it to 
phagocytize at baseline levels. These findings suggest that a snapshot of phagocytic 
activity, during this dependence-like state only, might give the impression that morphine 
increases phagocytic activity. 
 An equally important factor for phagocytosis, that was discussed but not directly 
assessed in the previously mentioned studies, is whether morphine changes the state of 
polarization of microglia and macrophages. It is generally believed that M2 cells are more 
phagocytic and have a greater role in debris removal than M1s (Kigerl et al. 2009; Tang 
and Le 2016). Thus, changes in the state of polarization of immune cells could also 
partially explain contradictory findings in phagocytic studies. Additionally, some studies 
have shown that the phagocytic index of M1 versus M2 polarized cells is different for 
microglia compared to macrophages, furthering the idea that subpopulations of these cells 
have different roles after injury. For instance, in vitro and in vivo studies in SCI mice 
showed that while all microglia and macrophages subtypes engaged in phagocytosis after 
injury, M1 microglia and M2 macrophages had the highest phagocytic capacity (Yao et 




macrophages after SCI to change phagocytosis could help shed light on this crucial 
immune function. Therefore, in the experiments described in this chapter I included 
fluorescent antibodies and examined differences in the phagocytic capacity of the M1 
(CD68) and M2 (MHCII) subpopulations of microglia and macrophages with and without 
morphine administration.  




Figure 24. Timeline for Experiment 3. 
 
 
 Experiment 3 was conducted according to Figure 24. Flow cytometry was used to 
compare the phagocytic activity of microglia and macrophages at the site of injury, in 
rodents that received morphine vs. vehicle (0.9% saline). To evaluate changes in the 
phagocytic function of these cells across time, morphine or saline were given for either 1, 
3, or 7 days post injury and tissue was collected 24 hours after the last drug administration 
as described in Chapter II (General Methodology). Briefly, after dissociating primary cells 




heterogenous mixture of cells using MACS separation in combination with anti-CD11b 
magnetic beads. The cells from the positive CD11b effluent were counted and used to 
conduct an ex vivo phagocytosis assay, by incubating the cells with FITC-coated 
polystyrene beads (1 m diameter) for 2 hours at 37C, 5% CO2. This 2 (morphine or 
vehicle) x 3 (days of morphine administration) experimental design used 48 rats (n = 6). 
To differentiate between the effects of surgery versus drug treatment, two additional sham 
groups were added at the day 7 timepoint (n = 6). Sham subjects followed the same 
surgical and drug administration regimen as their contused counterparts, with half of the 
shams receiving morphine and half receiving saline. All behavior analyses were conducted 
on subjects from the 7-day administration group to allow for a within-subjects comparison 
from day 1 to day 7 scores. 
 
Effects of Morphine on Locomotor Recovery 
Locomotor behavior was scored daily using the BBB scale (Basso, Beattie, and Bresnahan 
1995) to assess the effects of morphine on recovery. BBB scores are shown in Figure 25 
as mean converted BBB scores ( S.E.M) for the first seven days after surgery. A two-
way repeated measures ANOVA showed a main effect of day (F (6, 84) = 8.773, p < 
0.001) but not of treatment  
(F (1,14) = 2.824, p = 0.1150) on BBB scores. Locomotor scores on day one prior to drug 
treatment did not differ significantly between contused saline (1.75 ± 0.45) and contused 




 However, commensurate with previous locomotor assessments, our analysis 
showed a significant interaction between day post-surgery and treatment (F (6, 84) = 
7.821, p < 0.001). Post hoc comparisons using the Holm-Šídák method indicated that 
saline-treated rats had significantly higher BBB scores than morphine-treated rats on days 
6 and 7 post-surgery (t (98) = 2.877, p < 0.05; t (98) = 3.230, p < 0.05, respectively). 
Vehicle controls rats recovered to an average converted BBB score of 5.25 ± 1.42, while 
morphine-treated subjects recovered to an average converted BBB score of 2.05 ± 0.52. 
All sham rats, irrespective of treatment, had a converted BBB score of 12 (unconverted 
BBB score of 21) throughout the seven-day post-surgery assessment period. 
 
 
Figure 25. Effects of intravenous morphine on locomotor recovery. Scores from the 7-day group subjects 
were balanced on day one post-injury. Morphine significantly undermined locomotor recovery by day 7 


































































Effects of Morphine on Sensory Recovery 
The effects of morphine on sensory recovery for the first sever days following 
sham or contusion injury are illustrated in figure 25. Sensory recovery was evaluated 
through the assessment of thermal (tail-flick test) and mechanical reactivity (von Frey 
filaments) on the first and last day of treatment, immediately before and 30-min after the 
intravenous administration of morphine. 
 
Assessment of the Analgesic Efficacy of Morphine 
Morphine produced robust analgesia on thermal reactivity that persisted across the seven 
days of administration (Fig. 26A). Both sham and contused animals reached the maximum 
8-sec tail-flick latency after receiving morphine. A 3-way ANOVA revealed a significant 
main effect of drug treatment (F (1, 28) = 786.9, p < 0.0001). There were no effects of 
surgery (F (1, 28) = 0.0947, p = 0.7605) or day of treatment (F (1, 28) = 3.871, p = 0.0591) 
and no significant Surgery x Drug Treatment interactions. 
Morphine also produced robust analgesia on the mechanical reactivity test at all 
timepoints. A 3-way ANOVA revealed a main effect of surgery (F (1, 28) = 10.26, p < 
0.001), a main effect of drug treatment (F (1, 28) = 54.66, p < 0.0001), a Day x Treatment 
interaction (F (1, 28) = 7.604, p < 0.05), and a Surgery x Drug Treatment interaction (F 
(1, 28) = 10.26, p < 0.001),  on the motor response to mechanical stimulation (Fig. 26B). 
Sham subjects showed higher sensitivity to tactile stimulation than contused rats across 
all days. Morphine administration also resulted in less vocal responses to mechanical 




treatment (F (1, 28) = 6.68, p < 0.05), and no effect of surgery or significant interactions 
between drug treatment and surgery. We did not see evidence of tolerance to morphine 
developing across days. Analgesia on the thermal reactivity and mechanical stimulation 
tests persisted across the seven days of administration (Fig. 26, A-C).  
 
Assessment of opioid-induced hyperalgesia 
Thermal and mechanical reactivity were also assessed prior to drug administration to 
monitor the development of opioid-induced hyperalgesia. There were no significant 
differences in tail-flick reactivity between conditions on day one post-injury. While there 
was no main effect of Day of testing, our statistical analysis showed it approached 
significance (F (1, 28) = 3.796, p < 0.0615). There were no effects of surgery, drug 
treatment, or significant interactions (Fig. 26D).  
Conversely, evidence of opioid-induced hyperalgesia was observed on the 
mechanical reactivity test (Fig. 3, E-F). As with the assessment of tolerance, contused 
animals showed less motor reactivity to mechanical stimulation (F (1, 28) = 7.533, p < 
0.05).  There was also a main effect of Day of testing on motor reactivity (F (1, 28) = 
6.575, p < 0.05), where subjects across all groups showed higher motor reactivity to 
mechanical stimulation on day 7 compared to day 1.  There was a similar main effect of 
Day of testing on vocal reactivity to mechanical stimulation (F (1, 28) = 7.216, p < 0.05), 
and a significant Day x Treatment interaction (F (1, 28) = 7.769, p < 0.001). Post hoc 




in response to mechanical stimulation was significantly decreased in contused morphine-
treated rats on day 7 compared to day 1 (t (36) = 3.843, p < 0.001, Fig. 26F).  
 
 
Figure 26. Effects of morphine on thermal and tactile reactivity. Morphine produced robust analgesia 
on thermal (A) and tactile (B, C) reactivity. There was no reduction in the efficacy of morphine across days 
on either sensory test. Conversely, the development of hyperalgesia was observed by day seven on vocal 
response to tactile reactivity (F) test but not for thermal reactivity (D). Contused subjects treated with 
morphine displayed significantly lower thresholds for vocal (F), and a trend for reduction of motor (E), 
responses on the tactile reactivity test. Results shown as Mean ± S.E.M.  *p < 0.05, n=8. 
 
 
Exp. 3A: Phagocytic Activity of M1 Microglia and Macrophages 
Following the completion of the phagocytosis assay conducted with CD11b+ cells, 
selective antibodies were used to label activated M1 (CD68) microglia and macrophages 
that phagocytized FITC-beads. A total of 30,000 events per sample were recorded using 





























































































































































interest in the M1 set. In this experiment, we used MACS separation to select CD11b+ 
cells for our assay. Therefore, we first gated live leukocytes out of our CD11b+ 
population, using CD45 (leukocyte marker) against the Zombie dye (live/dead marker) as 
shown in Fig. 27A. To assess the effects on the peripheral vs. resident immune response, 
we used the CD45 marker (channel BV 421) to identify microglia (CD45low) and 
macrophages (CD45high), as previously done by others (Sedgwick et al. 1991; Ford et al. 
1995; Badie and Schartner 2000; Martin et al. 2017). Next, we identified phagocytic cells 
by selecting cells that exhibited high FITC fluorescence within microglia (CD45low) and 
macrophages (CD45high) (Fig. 27D). Additionally, we created a parallel gate to select M1 
(CD68+) cells from the microglia and macrophage populations (Fig. 27E). Lastly, we 





Figure 27. Flow cytometry gating strategy for M1 set in CD11b+ cells after phagocytosis assay. As 
only CD11b+ positive cells were used for this experiment, we first used CD45 and Zombie dye to select live 
vs. dead leukocytes (A). Microglia (CD11b+, CD45low) and Macrophages (CD11b+, CD45high) were 
identified using CD11b+ and CD45 antibodies (B). Divergent gates were created for both microglia and 
macrophages. First, individual gates to quantify phagocytic microglia and phagocytic macrophages were 
made selecting cells that incorporated the FITC-beads (C). A parallel gate to select M1 (CD68 marker) 






Temporal Quantification of Leukocytes in set M1 
Figure 28 shows the quantification of leukocytes (CD45+) from a total of 30,000 events 
(total of number cells) per sample from a CD11b+ population of spinal cord cells. Live 
leukocytes were negatively gated by selecting cells that did not incorporate the Zombie 
dye, as only dying cells with a compromised membrane display fluorescence. As we have 
shown previously (Aceves et al. 2019), our tissue processing protocol yields high cell 
viability as quantified with Countess device (Invitrogen). Consistently, our flow 
cytometry analysis revealed a low number of dead cells across all of our four conditions 
with no main effects of surgery or treatment (Fig. 28, B and E). However, there was a 
higher proportion (F (1, 20) = 3.502, p = 0.0760) and number of live leukocytes (F (1, 20) 
= 4.565, p < 0.05) in contused subjects compared to shams on day 7 (Fig. 28, A and D). 
Given that there are no significant differences in the number of dead leukocytes across 
surgical groups, it is likely that the higher number of live leukocytes observed in contused 
subjects is a result of increased expression of CD45 on immune cells due to the injury. 
There were no additional main effects or interactions on days 1 and 3 on the number of 
live or dead leukocytes.  
In Chapter III we reported that morphine administration increased the overall 
number of microglia and macrophages by day 3 in a heterogenous mixture of spinal cord 
cells. In this experiment consisting of only CD11b+ cells, we directly assess whether 
morphine changed the ratio of microglia to macrophages, or whether it increased both cell 
types evenly. We calculated the ratio of microglia to macrophages where a value above 




As expected, sham subjects had the highest ratio value (F (1, 20) = 5.439, p < 0.05) since 
there are practically no macrophages infiltrating the cord in these rats (Fig. 28C). In 
contrast, we can see that in contused subjects the microglia/macrophage ratio stays close 
to or below 1.0 reflecting macrophage infiltration. While there are no additional significant 
main effects or interactions on days 1, 3 or 7, there is a consistent trend towards a higher 
ratio of microglia to macrophages in morphine-treated contused subjects across all days 
(Fig. 28C).  
 
 
Figure 28. Quantification or Live and Dead Leukocytes, as well as the Ratio of Microglia to 
Macrophages in CD11b+ cells in set M1. Contused subjects show a significantly higher number (A) and 
percentage (D) of live (activated) leukocytes compared to sham subjects. As expected, sham subjects show 
a much higher microglia/macrophage ratio value (ratio > 1.0, C) indicating higher number of microglia. 
There was no significant effect of treatment with 1,3 or 7 days of morphine administration. Results shown 
as Mean ± S.E.M.  *p < 0.05, n=6. 
 
 












































































































































Analysis and Quantification of M1 Microglia Phagocytic Activity 
As in our previous studies, we further characterized the number of M1 microglia (CD68+) 
in our sample. Our statistical analyses show that, as mentioned above, most of the CD11b+ 
cells in sham subjects are microglia cells and therefore, the proportion and total number 
of microglia is significantly higher in shams (F (1, 20) = 59.10, p < 0.0001 and F (1, 20) 
= 14.01, p < 0.001, respectively) regardless of treatment, compared to contused animals 
(Fig. 29, A and E). Next, we estimated the number of phagocytic microglia by quantifying 
cells that displayed a FITC signal, as they are assumed to have phagocytized the 
fluorescent beads, as shown by others (Yao et al. 2014). There is a significant increase in 
the total number of phagocytic microglia in sham subjects (F (1, 20) = 13.87, p < 0.001, 
Fig. 29F) that mirrors their higher number of microglia. However, there is no significant 
difference in the overall proportion of phagocytic microglia between sham and contused 
subjects (F (1, 20) = 3.202, p = 0.0887, Fig. 29B). There were no additional main effects 
or interactions on days 1, 3 or 7 on the number or percentage of phagocytic microglia. 
Similarly, there was a significant increase in the total number of M1 microglia 
(CD68+) in sham subjects (F (1, 20) = 15.83, p < 0.0001, Fig. 29G) compared to contused 
animals, but no significant difference in the proportion of M1 glia between surgery 
conditions (F (1, 20) = 3.202, p = 0.0887, Fig. 29C). Interestingly, while not significant, 
morphine administration seems increase the number of CD68+ cells regardless of surgery 
(F (1, 20) = 4.232, p = 0.0530, Fig. 29G) and this effect seems to be primary driven by an 
increase in CD68+ cells in morphine-treated sham subjects where a post-hoc comparison 




morphine-shams and morphine-contused subjects on day 7 (t (20) = 4.032, p < 0.001, Fig. 
29G). Additionally, there is a significant increase on day 1 in the number but not the 
proportion of M1 microglia in contused-morphine rats compared to saline-treated animals 
(t (10) = 1.815, p = 0.0498, (t (10) = 1.545, p = 0.0766, respectively).  
 Lastly, when we look at the number of M1 microglia that have phagocytized beads, 
our statistical analyses show a significant increase in both proportion and number of 
phagocytic M1 glia in sham subjects (F (1, 20) = 8.404, p < 0.01, and F (1, 20) = 15.83, p 
< 0.001, respectively, Fig. 29, C and G) compared to contused rats. There were no 
additional main effects of drug or interactions for M1 phagocytic microglia on days 1, 3 
or 7.  
 
 
Figure 29. Quantification of Phagocytic M1 Microglia. Sham subjects show an overall increase in the 
proportion (A) and total number (D) of microglia cells compared to contused animals. Additionally, sham 
subjects show higher numbers of phagocytic microglia. Results shown as Mean ± S.E.M.  *p < 0.05, n=6. 
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Analysis and Quantification of M1 Macrophages Phagocytic Activity 
As described for microglia, we quantified the number of M1 (CD68+) phagocytic 
macrophages in a population of spinal CD11b+ cells. As predicted, on day 7, contused 
subjects, independent of treatment, show a significantly higher proportion and total 
number of macrophages (F (1, 20) = 156, p < 0.0001, and F (1, 20) = 60.90, p < 0.0001, 
respectively, Fig. 30, A and E) compared to sham rats.  No other main effects or 
interactions were seen on the number of macrophages on days 1 and 3. A similar effect of 
contusion injury can be seen throughout the rest of the measurements for macrophages in 
contused animals. There is a significant increase with contusion in the percentage and the 
total number of phagocytic macrophages (F (1, 20) = 9.121, p < 0.001, and F (1, 20) = 
64.76, p < 0.0001, respectively, Fig. 30 B and F) compared to shams. As well as a 
significant increase with injury in the percentage and total number of M1 (CD68+) 
macrophages (F (1, 20) = 85.55, p < 0.0001, and F (1, 20) = 129, p < 0.0001, respectively, 
Fig. 30, C and G) independently of treatment. Remarkably, while injured animals showed 
a higher number of phagocytic M1 macrophages (F (1, 20) = 137.1, p < 0.0001, Fig. 30H), 
the percentage of phagocytic M1 macrophages across all conditions was not significantly 
different (F (1, 20) = 0.4105, p = 0.5290, Fig. 30D). There was an additional effect of drug 
treatment on day 3 on the overall number of phagocytic macrophages, with morphine 
significantly decreasing the overall number of phagocytic macrophages but not the 
percentage (t (10) = 2,879, p < 0.05, and t (10) = 0.2491, p = 0.8083, respectively, Fig. 30, 
B and F) compared to saline-treated contused rats. Similarly, 3 days of morphine 




rats (F (10) = 2,317, p < 0.05, Fig. 30G) but not the overall proportion of cells (t (10) = 
0.5232, p = 0.6123, Fig. 30C) compared to saline-treated animals. There were no 
additional main effects or significant interactions on days 1, 3, or 7 for M1 macrophages.  
 
 
Figure 30. Quantification of Phagocytic M1 Macrophages. Sham subjects showed significantly less 
activation of macrophages in essentially all parameters measured, except the proportion of phagocytic M1 
macrophages. Additionally, by day 3 of administration there was a significant decrease in the total number 
of phagocytic macrophages (F) and M1 macrophages (G) in morphine-treated contused subjects, relative to 




Exp. 3B: Phagocytic Activity of M2 Microglia and Macrophages 
As with the M1 panel, following the completion of the phagocytosis assay, 
selective antibodies were used to label M2 microglia and macrophages in CD11b+ cells 
extracted from spinal cord tissue. A total of 30,000 events per sample (number of cells) 
were recorded using flow cytometry. As can be seen in Figure 8, the general gating 
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strategy used to identify cells of interest is identical to set M1 except for the use of MHCII 
as the M2 marker (Fig. 31E). 
 
 








Temporal Quantification of Leukocytes in Set M2 
 Figure 32 depicts the quantification of leukocytes (CD45+ cells) from a sample of 
30,000 CD11b+ spinal cord cells. As described above, live versus dead cells were selected 
based on the incorporation of the Zombie dye. While the viability of our cells remained 
high across all testing timepoints, as expected, the proportion and total number of dead 
leukocytes was higher in contused subjects (F (1, 20) = 18.79, p < 0.0001, and F (1, 20) = 
18.81, p < 0.0001, respectively, Fig. 32, B and D) compared to sham rats on day 7. 
However, the number of dead cells for contused and sham subjects remains relatively low, 
thus, while the difference might be statistically significant it might not be biologically 
relevant.  There is also a significant effect of drug treatment on day 3 with saline-treated 
animals showing a higher proportion and total number live leukocytes (t (10) = 2.50, p < 
0.05, and t (10) = 2.501, p < 0.05, respectively, Fig. 32, A and D) compared to morphine-
treated contused rats.  
 Next, we estimated the ratio of microglia to macrophages to understand whether 
morphine biases the recruitment of one cell type over the other. This ratio was calculated 
by dividing the % microglia / % macrophages with values above 1.0 indicate a higher 
proportion of microglia cells. As expected, sham subjects displayed a significantly higher 
ratio (F (1, 20) = 9.480, p < 0.001, Fig. 32C) compared to contused animals.  On day 3, 
the microglia/macrophage ratio was significantly higher in morphine-treated contused 





Figure 32. Quantification or Live and Dead Leukocytes, as well as the Ratio of Microglia to 
Macrophages in CD11b+ cells in set M2. Contused subjects show a significantly higher number (B) and 
percentage (E) of dead leukocytes compared to sham subjects. As expected, sham subjects show a much 
higher microglia/macrophage ratio value (ratio > 1.0), indicating a higher number of microglia. Additionally, 
morphine-treated rats also had a significantly higher microglia/macrophage ratio compared to saline-treated 
animals on day 3 (C). There was no significant effect of treatment with 1, 3 or 7 days of morphine 
administration. Results shown as Mean ± S.E.M.  *p < 0.05, n=6. 
 
 
Analysis and Quantification of M2 Microglia Phagocytic Activity 
As in Exp. 3A, we further quantified the number of M2 (MHCII+) microglia as well as 
their phagocytic activity by looking at their expression of FITC fluorescent signal emitted 
by the engulfed beads. There was a significant increase in the proportion of microglia cells 
in sham subjects compared to contused rats, as most CD11b+ cells in intact animals are 
expected to be resident microglia (F (1, 20) = 30.48, p < 0.0001, Fig. 33A). There was 
also a significant increase in the proportion but not the total number of microglia in 


















































































































































morphine-treated rats on day 3 (t (10) = 2.258, p < 0.05 and t (10) = 1.267, p = 0.2338, 
respectively) compared to control animals. There were no main effects or interactions in 
the proportion or total number of phagocytic microglia across any of our testing days (Fig 
33, B and F). However, we did see a significant increase in proportion and total number 
of MHCII+ microglia in saline-treated animals (t (10) = 2.935, p < 0.05 and t (10) = 2.386, 
p < 0.05, respectively, Fig. 33, C and D), compared to morphine-treated rats on day 3.  




Figure 33. Quantification of Phagocytic M2 Microglia. Sham subjects show an overall increase in the 
proportion (A) but not the total (E) of microglia cells compared to contused animals. Additionally, saline-
treated contused subjects showed a higher proportion (C) and total number (G) of M2 microglia. Results 
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Analysis and Quantification of M2 Macrophages Phagocytic Activity 
As described for M2 microglia, we quantified the number of M2 (MHCII+) macrophages 
in a sample of 30,000 CD11b+ cells. As before, on day 7, contused subjects independent 
of treatment, showed a significantly higher proportion and total number of macrophages 
(F (1, 20) = 36.01, p < 0.0001, and F (1, 20) = 37.83, p < 0.0001, respectively, Fig. 34, A 
and E) compared to sham rats. There was an additional main effect of treatment on day 3 
where saline-treated rats had a significantly higher proportion and total number of 
macrophages (t (10) = 2.254, p < 0.05, and t (10) = 2.768, p < 0.05, respectively) compared 
to morphine-contused rats. No other main effects or interactions were seen on the number 
of macrophages on day 1. Similarly, contusion injury significantly increased the 
percentage and total number of phagocytic macrophages on day 7 (F (1, 20) = 36.01, p < 
0.0001, and F (1, 20) = 37.83, p < 0.0001, respectively, Fig. 34, B and F) compared to 
shams. There was also a significant increase in the total number but not the proportion of 
phagocytic macrophages on day 3 in saline-treated rats (t (10) = 2.682, p < 0.05, and t (10) 
= 0.309, p = 0.763, respectively, figure 34, B and F) compared to morphine-contused 
animals. Additionally, contusion injury increased the total number but not the proportion 
of MHCII+ macrophages on day 7 (F (1, 20) = 14.62, p < 0.001, and F (1, 20) = 37.83, p 
< 0.0001, respectively, Fig. 34, C and G) compared to sham subjects. Interestingly, our 
results show that on day 3, morphine significantly reduced the proportion and total number 
of MHCII+ macrophages (t (10) = 2.682, p < 0.05, and t (10) = 0.309, p = 0.763, 
respectively) compared to saline-contused subjects. Comparably, the contusion injury 




(F (1, 20) = 5.503, p < 0.05, and F (1, 20) = 14.62, p < 0.001, respectively, Fig. 34, D and 
H) compared to sham subjects. Again, on day 3, morphine significantly reduced the 
percentage and total number of phagocytic MHCII+ macrophages (t (10) = 1.899, p < 
0.05, and t (10) = 2.073, p < 0.05, respectively) compared to contused saline-subjects. 
There were no main effects or significant interactions on day 1 for MHCII+ macrophages.  
 
 
Figure 34. Quantification of phagocytic M2 macrophages. Sham subjects showed significantly less 
activation of macrophages in essentially all parameters measured, except the proportion of M2 macrophages. 
Additionally, by day 3 of administration there was a significant decrease in the total number of phagocytic 
macrophages (F) M2 macrophages (G), and phagocytic M2 macrophages (H) in morphine-treated contused 
subjects, relative to saline controls, as well as their percentage (C and D, respectively). Results shown as 




The experiments in this chapter were conducted to assess whether repeated morphine 
administration after SCI changes the phagocytic ability of microglia and macrophages. 
Our flow cytometry analysis shows that morphine administration did not change the 
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overall percentage of microglia (CD45Low) or macrophages (CD45High) that engaged in 
phagocytosis of FITC-beads. However, as previously mentioned, M2 macrophages and 
M1 microglia are the most active of the phagocytic subtypes (Yao et al. 2014). Indeed, 
when we quantified phagocytic activity within the subpopulations of immune cells, we 
found that morphine administration decreased the proportion of M2 macrophages that 
phagocytized fluorescent beads. Surprisingly, however, morphine did not alter the 
phagocytic capacity or the total number of M1 microglia after SCI.  
 A suboptimal performance by M2 macrophages after SCI can delay the clearance 
of myelin debris and lead to protracted accumulation of myelin debris at the injury site, 
preventing axonal growth and remyelination (Perry, Brown, and Gordon 1987; Imai et al. 
2008). Indeed, a number of studies have grafted macrophages directly into the spinal 
lesion and have shown that grafts enhance recovery after SCI in rodents, but only if the 
macrophages grafted are polarized towards the M2 phenotype (Bomstein et al. 2003; 
Francos-Quijorna et al. 2016; Jeong et al. 2017). These experiments highlight an 
unintended consequence of morphine administration. While some studies suggest that 
morphine might interfere with the phagocytic ability of microglia and macrophages 
(Rojavin et al. 1993; Lazaro et al. 2000; Hu et al. 2018; Bosshart 2010; Ma et al. 2015), 
the data presented here suggests that extended morphine administration specifically 
reduces the phagocytic ability of M2 macrophages after SCI. However, a morphine-
induced increase in microglia and macrophage expression, reported in Chapter III, may 
compensate in part for the lower M2 macrophage phagocytic index. There is also likely a 




disruption of phagocytic function may be detrimental. Further studies are needed to assess 
the efficacy of myelin removal in vivo, with and without morphine administration.  
Additionally, morphine seems to shift the microglia/macrophage ratio toward 
microglial expression. Typically, after an SCI there is an even number of resident 
microglia and infiltrating macrophages between days 3-7 after injury (ratio = % microglia 
/ % macrophages) (Popovich, Wei, and Stokes 1997). However, we found that after 3 days 
of I.V. drug administration there is a shift towards a higher proportion of microglia than 
macrophages in morphine-treated rats (ratio = 1.692  0.25) compared to saline-treated 
animals (ratio = 1.106  0.15). Therefore, despite our data showing a similar proportion 
of phagocytic cells in morphine compared to saline controls, a shift in the 
microglia/macrophage ratio at a timepoint where microglia have a larger role for 
phagocytosis suggests that morphine might indirectly enhance microglial phagocytic 
activity by increasing the overall expression of microglia. Thus, the net effect of morphine 
administration may still be an increase in phagocytosis through the overexpression of 
microglia.   
Unfortunately, increased microglial phagocytosis can be problematic for injury 
resolution. In rodents, reducing microglial phagocytic activity but not macrophage 
phagocytosis after SCI, resulted in improved locomotor recovery and neuronal viability 
(Greenhalgh et al. 2018; Yip et al. 2019). In vivo and in vitro assays have shown that 
microglia activated by inflammatory signals are more likely to engage in phagoptosis, 
which happens when immune cells phagocytize stressed-but-viable neurons (McArthur et 




post-injury could partially explain the dramatic increase in neuronal cell death we have 
reported by day 7 after injury in morphine-treated rats (Hook et al. 2017).  
 It is also worth noting that while the use of M1/M2 markers is helpful to conduct 
a more in-depth investigation of the subpopulations of immune cells, there is evidence to 
suggest that the dichotomous sorting of microglia/macrophages might only exist in in vitro 
assays and oversimplifies the intricacies of immune cells that exist in in vivo models. It is 
now more widely accepted that the M1 and M2 phenotypes are the extreme ends of a 
continuum of profile activation. Supporting this notion is the ongoing challenge to 
accurately identify markers to label M1 and M2 cells. While a number of proteins have 
emerged as relevant labels for these cells, there is overlap in the expression of even the 
most commonly used “M1” and “M2” markers. In addition, researchers have proposed 
that M2 cells can be further divided into three subsets: M2a, M2b, and M2c. Given that in 
the present experiment we only included 2 markers to characterize our cell populations, it 
is likely we missed some phenotypes during our assay. Indeed, our data shows that 
morphine administration decreases the expression of M2 (MHCII+) microglia (Fig. 33C) 
but it does not increase the expression of M1 (CD68+) microglia (Fig .29C). By deduction, 
this implies that not all of the cells in our samples have been labeled with either MHCII 
or CD68. We should be cautious about drawing strict conclusions in terms of M1 and M2 
distinctly.   
 In summary, our data shows that repeated morphine administration after SCI in 
rats, might indirectly increase microglial phagocytosis which has been associated with an 




that morphine administration reduces favorable M2 macrophage phagocytosis ex-vivo. 
Whether the suppressive effect of morphine on M2-mediated phagocytosis impacts cell 
survival or recovery in an in vivo model, or whether the morphine-induced increase of the 
overall expression of microglia and macrophages compensates for the reduced phagocytic 
activity, remains to be determined. In future studies, it would be interesting to explore if 
M1 microglia phagocytize viable neurons at a higher rate after morphine administration 
and whether reduced M2 macrophage phagocytosis results in an increase of cell debris 






CHAPTER VI  
GENERAL DISCUSSION AND CONCLUSION 
 
The goal of the experiments described in this thesis was to identify key opioid-
immune interactions that undermine recovery of function in a rodent SCI model. 
Consistent with previous reports from our laboratory, we found that intravenous morphine 
administration increases the total number of activated microglia and macrophages at the 
site of injury. More specifically, we found that morphine increases the expression of both 
M1- and M2-like immune cells, as well as increasing the expression of KORs on these 
cells. Additionally, we found that morphine administration changes critical functions of 
immune cells that are integral to recovery of function after SCI. Our western blot results 
suggest that after SCI, morphine increases the expression of -arrestin pathway proteins 
linked to the production of pro-inflammatory cytokines and apoptotic signals. Importantly, 
we found that morphine upregulates the production of dynorphin and pro-dynorphin by 
microglia/macrophages, which may induce neurotoxicity. Unfortunately, however, we 
hypothesize that morphine might indirectly increase the phagocytosis of stressed-but-
viable neurons by M1 phagocytic microglia after the lesion, without proportionally 
enhancing the function of M2 phagocytic macrophages responsible for cleaning up cell 
debris. In the following sections I will discuss the effect of morphine on the expression 
and function of microglia/macrophages, and the potential implications for the recovery of 





Effect of Morphine on the Expression of Immune Cells 
As we have reported with intrathecal (i.t) morphine administration (Aceves et al. 
2019), we found that extended intravenous (i.v.) administration of morphine dramatically 
increases the expression of microglia and macrophages at the site of lesion after SCI. 
However, in comparison to i.t. administration where infiltration of immune cells is 
noticeable 24 hours after a single dose of morphine, the peak of infiltration in our i.v. 
model is observed after 3 days of drug administration. The delay in immune cell 
infiltration with systemic (intravenous) versus direct (intrathecal) administration of 
morphine, supports the notion that morphine plays an important role in the exacerbated 
immune response. While in our own study we cannot determine whether morphine 
increases proliferation or enhances the recruitment of immune cells, in vitro studies have 
shown that morphine activation of ORs promotes the proliferation of microglia and 
macrophages (Xu et al. 2007; McLennan et al. 2008; Hutchinson et al. 2011). 
Based on previous findings in the laboratory, suggesting that IL-1 expression 
levels are increased by morphine (Hook et al. 2011), we hypothesized that i.v. morphine 
would not only increase the proliferation of microglia/macrophages but that it might bias 
their activation toward a M1 pro-inflammatory phenotype. Contrary to this hypothesis, we 
found that morphine significantly increased the expression of both the M1 and M2 type of 
cells. In fact, unexpectedly, our flow cytometry analysis showed that morphine increases 
the expression of M2s more robustly than that of M1 cells. This finding was surprising as 
induction or transplantation of M2 cells, particularly M2 macrophages, has been reported 




unlike M1 cells that showed persistent elevation, the increase of M2 cells was transitory 
and their expression was practically back to baseline levels after 7 days of administration. 
Indeed, M2 cells are less resistant to stress and inflammation than M1 cells, and are 
generally only found transiently around the injury (Kigerl et al. 2009). Some laboratories 
have even shown that M2 cells, which are known for their elevated phagocytic capacity, 
start expressing M1-like markers when they phagocytize myelin debris (Wang et al. 2015). 
Thus, it is possible that the initial surge in M2 cells, which would be expected to be 
beneficial, eventually transforms into M1 pro-inflammatory cells that worsen the injury. 
Alternatively, the loss of M2 cells between day 3 and day 7, could also be due to their 
fragile nature. M2 cells are more susceptible to the inflammatory environment of the injury 
and die at higher rates than M1 cells. Indeed, while acute morphine administration induces 
proliferation, extended administration of morphine (over 5 days) induces apoptosis of 
microglia and macrophages (Emeterio, Tramullas, and Hurle 2006).  
The death of M2 macrophages can be especially problematic as they accumulate 
iron during phagocytosis. If the cell membrane gets compromised this iron then leaks out 
of the M2 cells in the form of toxic ferrous iron, causing free radical damage (Rathore et 
al. 2008; David and Kroner 2011). Moreover, astrocytes that would normally aid with the 
removal of excess of iron after SCI (Rathore et al. 2008) are practically undetectable in 
SCI rats after 7 days of morphine administration (Hook et al. 2017). Thus, it is possible 
that in our model, morphine produces a biphasic immune response. Initially, there may be 




that results in M2 cell death, free radical damage, and further neurodegeneration at the 
injury site.  
Future studies, where cells are simultaneously tagged with multiple M1 and M2 
markers, are required to investigate whether M2 cells are dying or transforming into M1-
like cells. Indeed, a limitation of the present study is the use of a single marker for the 
distinct subpopulations of microglia and macrophages. The M1/M2 classification was 
established in in vitro models but recent literature shows that it does not capture the 
complexity of the immune reaction that occurs in vivo. While the markers available to 
identify these populations do still provide valuable information about the specific function 
of these cell populations, it is now more accepted that the M1 and M2 classification are 
the extreme ends of an activation continuum. This is evidenced by numerous reports of 
overlap in the expression of even the most commonly used M1 and M2 markers, as shown 
in Table 4. Therefore, we must be reticent about drawing conclusions based on a strict 
classification system. Nonetheless, the heterogeneity in phenotype, and the contrasting 
functions of microglia and macrophages, has made them ideal targets for the development 
of pharmacological treatments focused on the immune response. By selecting immune 
populations that are phenotypically similar and that can be labeled as M1 or M2 cells, we 
can better understand the functional significance of SCI treatments that change the 
distribution of immune cells. 
The challenges to accurately classify M1 and M2 cells, especially under highly 
inflammatory conditions like SCI, have limited the number of studies that have attempted 




of immune cells. Indeed, to our knowledge, no previous paper has yet described the 
expression of KORs on M1/M2 subpopulation of microglia and macrophages - with or 
without morphine administration. Here, we show that extended morphine administration 
increases the proportion of KOR-expressing microglia and macrophages in contused 
subjects, as well as the proportion of M1 and M2 microglia/macrophages expressing 
KORs. While in this particular experiment we did not assess whether morphine only 
increases the expression of KORS or whether it also activates these receptors, previous 
work from our laboratory has shown that KORs are sufficient and necessary for the 
negative effects of morphine (Aceves, Mathai, and Hook 2016; Aceves et al. 2017). In the 
subsequent sections I will discuss how morphine changes key function of microglia and 
macrophages, possibly through the activation of KORs or through combined activation of 














Table 4. Review list of typical M1 and M2 markers used in the literature. 
Marker M1 M2 
Arg-1 (El Kasmi et al. 2008; Jablonski et 
al. 2015) 
(Chhor et al. 2013; Jablonski et al. 2015; 
Francos-Quijorna et al. 2016; Gensel et al. 
2017; Yip et al. 2019) 
CD206  (Bellon et al. 2011; Chhor et al. 2013; 
Kobayashi et al. 2013; Jablonski et al. 
2015; Francos-Quijorna et al. 2016; 
Gensel et al. 2017) 
CD86 (David and Kroner 2011; Chhor et 
al. 2013; Gensel et al. 2017; 
Kobayashi et al. 2013) 
(David and Kroner 2011; Roszer 2015)  
CD68 (Kobayashi et al. 2013; Morganti et 
al. 2015; Dong et al. 2016) 
(Dong et al. 2016; Wang, Smith, et al. 
2019) 
MHCII (David and Kroner 2011; Gensel et 
al. 2017) 
(Abramson and Gallin 1990; Bomstein et 
al. 2003; David and Kroner 2011; 
Lawrence and Natoli 2011) 
 
 
Functional Effects of Morphine Activation of Opioid Receptors 
In addition to increasing the proliferation of microglia and macrophages, morphine 
can also alter the immune response by activating opioid receptors expressed by these cells 
and changing key immune functions. Our western blot results reported in Chapter IV show 
that in contused rats, intravenous morphine administration increases levels of -arrestin, 




microglia/macrophages. Notably, this increase was only apparent when we collected the 
tissue while morphine was still present in the system of rats. In assays where we delayed 
tissue collection by 24-hours, and morphine has been washed out, we do not see significant 
differences between saline- and morphine-treated contused rats. These data suggest that 
the effects we observed are more likely due to morphine actively binding to receptors 
rather than due to morphine inducing long-lasting upregulation of signaling pathways in 
microglia/macrophages. These data also demonstrate the sensitivity of the timing of the 
assay, as they could reveal differences between the actions of morphine and changes due 
to morphine withdrawal.  
The most notable finding from our western blot analysis was that morphine 
increases the production of pro-dynorphin and dynorphin. Dynorphin is a peptide that is 
CREB-dependent, with transcription regulated downstream from ERK 1/2 activation. 
Dynorphin is endogenously produced under normal physiological conditions and after SCI 
its expression increases and correlates with the severity of the injury (Przewlocki, 
Shearman, and Herz 1983; Cox et al. 1985; Faden et al. 1985; Faden 1990). Physiological 
levels of dynorphin activate KOR receptors in neurons to mediate analgesia (Mika, Obara, 
and Przewlocka 2011). However, while neuron-mediated dynorphin is analgesic, glia-
mediated production of dynorphin is thought to have detrimental effects (Xu et al. 2004; 
Svensson et al. 2005).  After partial sciatic nerve ligation, endogenous release of spinal 
dynorphin induces KOR immunoreactivity in neurons and astrocytes in the spinal cord 
dorsal horn. KOR knock-out or pretreatment with norBNI, a KOR antagonist, induces 




an opioid-independent mechanism that induces spinal nociception through the activation 
of p38 MAPK in microglia (Svensson et al. 2005). Analogously, studies done in rodent 
models of SCI show that administration of supra-physiological levels of dynorphin 
directly to the spinal cord induces paraplegia in normal rats (Long et al. 1988; Hu et al. 
1996). In SCI models, high concentration of dynorphin or extended exposure to this 
neuropeptide induces neurotoxicity, increases SCI dysfunction, and promotes 
hyperalgesia (Faden 1990; Laughlin et al. 2000; Adjan et al. 2007; Mika et al. 2010). 
Therefore, while we had originally hypothesized that our negative effects were due to 
the activation of KOR on microglia/macrophages, it is possible that instead 
microglia/macrophages increase dynorphin production which then activates KORs found 
in neurons. Previous data from our laboratory, showing that the negative effects of 
morphine can be blocked with pre-treatment of minocycline (glia inhibitor) and norBNI 
(KOR antagonist), also support this alternative hypothesis. It is possible that by blocking 
microglia/macrophage activation with minocycline, which also reduces dynorphin mRNA 
levels in glia (Mika et al. 2010), we are preventing excessive glial production and release 
of dynorphin. In a similar way, if we blocked KOR activation in neurons with our norBNI 
treatment, theoretically, we would prevent the toxic and unrestrained activation of neurons 
by glia-produced dynorphin. To test if the effects we see are dependent on the activation 
of opioid receptors, we could use naloxone to block ORs before administering morphine 
and then quantify protein expression in microglia and macrophages. Alternatively, we 




morphine, and investigate whether it blocks the effects on recovery with or without 
inducing additional changes at the cellular level.   
 Indeed, while in the first set of experiments described in Chapter III we focused 
on the expression of KORs on microglia/macrophages based on our initial hypothesis, 
there is little doubt that activation of other ORs can also contribute to the effects of 
morphine and should be considered. While we have not assessed whether morphine also 
increases the expression of other classic and non-classic ORs, we know that morphine can 
bind and activate all existing ORs on immune cells. Indeed, in our western blot analysis 
we cannot determine if morphine is acting through the kappa receptor alone or a 
combination of multiple opioid receptors. For instance, other studies show that TLRs 
might play an important role mediating neurotoxic effects of morphine. TLR4 activation 
in microglia leads to increased production of TNF and other pro-inflammatory cytokines 
(Tanga et al. 2005 from Buchanan et al., 2010) that target neurons and alter their function 
(Buchanan et al. 2010). TLR4 activation also mediates the increase in mechanical 
allodynia after morphine administration in a rat model or neuropathic pain, by increasing 
the mRNA and protein expression of TLR4, TNF, IL-1B, and NLRP3 (Ellis et al. 2016). 
While we have shown that activation of KORs is needed to induce the negative effects of 
morphine, and that these effects cannot be prevented with a TLR antagonist (Aceves, 
2015, unpublished), it is still possible that activation of other ORs exacerbate morphine’s 
neurotoxic effects. Further studies are needed to understand how morphine affects the 
expression and function of other ORs since they have been shown to play important roles 




Based on the data I have shown so far, we speculate that opioid-immune 
interactions are driving the negative effects of morphine on motor recovery after SCI. The 
release of pro-inflammatory cytokines and dynorphin by immune cells might be making 
neurons more vulnerable to dying or being phagocytized. As the existing literature 
suggests that repeated opioid administration can suppress the phagocytic function of 
macrophages, the excessive cell death observed in our SCI model highlights the 
importance of understanding the immune function in this context.  It is crucial to determine 
the capacity of these immune cells to clear cellular debris and target dying neurons after 
morphine administration and SCI.  
 
Effect of Morphine on the Phagocytic Function of Immune Cells 
Independently of whether dynorphin production is the main mechanism or one of 
the contributing factors increasing neurotoxicity, we know that morphine-treated contused 
rats exhibit significantly more cell death than saline controls (Hook et al. 2017). The 
damaging effect of morphine on cell survival highlights the importance of efficient debris 
removal by phagocytic immune cells. Unfortunately, commensurate with the literature, 
our flow analysis showed that repeated morphine administration reduced the proportion 
of phagocytic M2 macrophages. However, morphine did not affect M1 microglia activity 
levels. Based on the results from Chapter III, we also know that morphine increases the 
total number M2 macrophages. It is possible that increased expression partially 




activity unaffected. In this section I will discuss the importance of efficient phagocytic 
activity for our model and how it is affected by morphine. 
Our initial assessment of the phagocytosis assay revealed no changes in the overall 
percentage of microglia/macrophages that engage in phagocytic activity. However, after 
evaluating the most phagocytic subpopulations of immune cells, M1 microglia and M2 
macrophages, we found important differences between morphine and saline treated SCI 
rats. First, as phagocytic function is primarily attributed to M2 macrophages the reduced 
proportion of M2 phagocytic cells would have significant implications for recovery of 
function. Clearance of apoptotic debris by microglia and macrophages reduces the 
production of pro-inflammatory cytokines and prevents further neuronal death. Also, 
damaged neurons and myelin release molecules that inhibit axonal regeneration and 
prevent remyelination (Takahashi, Rochford, and Neumann 2005; Vallieres et al. 2006). 
Delays in cell debris removal worsens the injury outcome and interferes with recovery. 
Ironically, if M2 cells are also going through apoptosis at higher rates, then even greater 
phagocytic activity would be required from the same cells that are dying.  
It is important to note that in our phagocytosis assay, we see a decrease in the 
percentage of both M1 and M2 macrophages with morphine administration, that was not 
observed in the first set of experiments. Thus, it is possible that in this phagocytosis assay 
we are targeting different subpopulations of microglia/macrophages than those assayed in 
Chapter III. To address limitations on our flow cytometry experiments from Chapter III 
that did not allow us to directly compare cell expression between sets M1 and M2 given 




we used alternative M1 and M2 markers that theoretically were supposed to target the 
same cell populations but had more commercially available varieties of fluorescent 
conjugates. In the phagocytosis flow experiments, we switch the M1 maker from CD86 to 
CD68 and the M2 marker from CD206 to MHCII. More recent nomenclature systems 
describe 4 distinct subtypes of M2 cells: M2a, M2b, M2c, and M2d based on their distinct 
genetic profiles and the type of stimulus that induces each particular phenotype 
(Mantovani et al. 2004). Unfortunately, just as there is discrepancy about which markers 
better describe M1 and M2 populations (Table 4), there is also debate on which markers 
are more representative of each M2 subpopulation and the specific functions associated 
with them (Mantovani et al. 2004; David and Kroner 2011; Chhor et al. 2013). The two 
most relevant M2 subpopulations for SCI research are M2a and M2b macrophages. M2a 
cells are thought to promote tissue repair and express high levels of CD206 (Chhor et al. 
2013). M2b macrophages, on the other hand, regulate the length and scale of the immune 
response, and express high levels of C-C Motif Chemokine Ligand 1(CCL1) (Wang, 
Zhang, et al. 2019). However, the distinctions between these 2 subtypes is vaguer in 
relation to other functions and markers. There is debate on whether M2a or M2b cells are 
more phagocytic, and whether MHCII is mostly expressed by M2a , M2b, or both cell 
types (David and Kroner 2011; Wang, Zhang, et al. 2019; Roszer 2015).  Thus, while we 
are targeting key M2 subpopulations for SCI, either M2a or M2b depending on the 
classification system used, it is still possible we failed to capture at least one critical 




Interestingly, M1 microglia, the other highly phagocytic phenotype, were not 
affected by morphine administration. Thus, the net effect of morphine administration 
might rely more heavily on M1 microglial phagocytosis than on M2 macrophages. 
Unfortunately, unlike the beneficial effects that have been reported from enhancing the 
rate of phagocytosis of M2 macrophages, evidence suggests that M1 microglial 
phagocytosis could have negative consequences after SCI. M1 microglia are more likely 
to engage in phagoptosis of stressed-but-viable neurons, especially within an 
inflammatory context (Brown and Neher 2014). Additionally, extended release of pro-
inflammatory cytokines and dynorphin can stress neurons and make them more vulnerable 
to phagoptosis by microglia. Inflammatory stress causes neurons to put out “eat me” 
signals, like exposing phosphatidylserine, which encourages microglia to phagocytize 
them while they are still viable (Brown and Neher 2012; Brown and Vilalta 2015). 
Additionally, activation of TLR4 receptors in microglia can also increase phagoptosis of 
vulnerable neurons stressed by inflammatory signals (Brown and Vilalta 2015). 
The data shown in this study suggests that perhaps the amount of phagocytic 
activity is not as important as the type of phagocytosis being carried out by immune cells. 
Future experiments are needed to directly assess whether inflammatory signals 
exacerbated by morphine administration stimulate M1 microglial phagoptosis of stressed-
but-viable neurons at higher rates than in saline animals. Additionally, further studies 
could explore whether an increase in subsets of M2 cells (CD206+, Ch. III) would be 
enough to compensate for low M2 phagocytic activity or if there is an abnormal 




our model. These studies can also assess how the timing of cell collection changes 
phagocytic activity of immune cells. In our study, we conducted the phagocytic assay 24 
hours after the last drug administration. However, as we saw in Chapter III, the effects of 
morphine during activation might differ significantly from the effects we observed during 
morphine withdrawal.  
Moreover, it should be noted that most ex vivo and in vitro studies, including ours, 
are conducted with isolated populations of microglia and macrophages. However, in vivo, 
microglia and macrophages are in constant communication with neurons, astrocytes, and 
other immune cells. Isolated systems are unlikely to capture the complexity of the immune 
response in vivo where immune cells continuously receive signals and feedback from 
neighboring cells. For instance, Hu and colleagues (2018) found that morphine 
administration after SCI decreased microglial phagocytosis by altering the communication 
between astrocytes and microglia. In their study, they showed that morphine induces the 
release of extracellular vesicles by astrocytes, which are then taken up by microglia and 
processed within the endosomes. The engulfment of the morphine-stimulated vesicles 
decreases microglial phagocytosis and increases the production of pro-inflammatory 
cytokines (Hu et al. 2018). We have yet to explore the full effect of morphine 
administration on the function of astrocytes and on glia-astrocyte communication in 
contused rats. Therefore, we cannot know whether the effect of morphine on phagocytic 





However, indications from the literature suggest that allowing cells to interact, in 
vivo or in vitro, can change or accentuate their functions. For example, when microglia 
are co-cultured with astrocytes the production of pro-inflammatory cytokines by microglia 
in response to LPS stimulation is stronger than when microglia are cultured by themselves 
(Barbierato et al. 2013). Reactive astrocytes can also stimulate microglial phagocytosis 
during the acute phase of neuroinflammation (Lian et al. 2016). On the other hand, 
activated microglia can impact the astrocytic response. Microglia production of pro-
inflammatory cytokines like IL-1a and TNF can reduce astrocytic functions that are 
important for neuroprotection (Liddelow et al. 2017). Additional evidence also suggests 
that astrocytes and microglia can influence each other’s proliferation after SCI (Haan et 
al. 2015). All this evidence strongly suggests that there is an important feedback loop 
between the two cell types and points to an important role in how they collaborate after an 
injury. Additional studies are needed to explore the influence or morphine on the glia-
astrocyte axis and its impact on the resolution of an SCI.  
Nonetheless, to progressively increase our understanding about how morphine 
affects the immune response to SCI in vivo, we first need to parse out the effects of 
morphine on isolated cell systems. Overall, the evidence shown here suggests that 
morphine administration impacts the expression and function of microglia/macrophages. 
We believe that interactions between the opioid and immune system are at the core of the 
negative effects of morphine on recovery of function. The experiments outlined in this 
thesis will serve as building blocks for future studies that delve into more complex cell-






Figure 35. Proposed mechanism of action of morphine's neurotoxic effects after SCI. 
 
Opioids are powerful analgesics that have been ubiquitously prescribed in the 
clinic due to their effectiveness to relieve severe and debilitating pain. Unfortunately, in 
our rodent model of SCI, the analgesic relief comes at the expense of functional recovery. 
Yet, as we currently do not have better analgesic alternatives, and effective pain 
management is needed to improve the prognosis of SCI patients, it is important that we 
understand the underlying mechanisms behind the negative effects of morphine to 
improve their safety in the clinic.  
In this document I discussed the idea that interactions between the opioid and the 
immune system can radically change the outcome of an inflammatory disease or injury. 
As reviewed earlier, the literature provides vast evidence showing that opioids can 
influence the proliferation, cell death, and function of immune cells by activating ORs 




numbers of activated microglia and macrophages at the center of the lesion, and the 
expression of KORs on them. We also found that repeated administration of morphine 
increases MAPK signaling and dynorphin production in microglia/macrophages. Lastly, 
our data shows that morphine might be reducing the proportion of M2 phagocytic 
macrophages needed to promptly remove injury debris and death cells. This effect might 
shift the preponderance of phagocytic activity to be conducted by M1 microglia. 
Unfortunately, morphine-mediated inflammation might be inducing M1 microglia to 
engage in phagoptosis of stressed-but-viable neurons. Collectively, these molecular 
changes will result in increased neuronal loss. For this reason, it is important that we fully 
understand the molecular consequences of opioid administration after SCI and its potential 
to affect recovery of patients living with an SCI.  
Based on the existent literature and our own data, I propose that morphine activates 
ORs found on microglia/macrophages and changes their function to induce neurotoxic 
factors that further exacerbate the secondary injury cascade (Fig. 35). SCI initially triggers 
a series of immune and inflammatory signals in response to cellular damage from the 
injury. These signals serve to activate immuno-competent cells and recruit peripheral 
immune cells to infiltrate the injury. Morphine administered immediately after the injury 
further increases the proliferation and activation of these cells at the center of the lesion 
(Fig. 35, step 1). While microglia/macrophages are normally recruited to aid with debris 
removal, containment of inflammatory material, and tissue repair, an excessive response 
by immune cells exacerbates the injury and diminishes recovery in SCI rodents (David 




induces these deficits by increasing the expression of opioid receptors and activating them 
to modify the innate response to the injury (Fig. 25, step 2).  We believe that morphine is 
acting through these opioid receptors to activate proteins related to the -arrestin pathway, 
including ERK 1/2 and p38 MAPK, which are known to activate inflammatory and 
apoptotic pathways (Fig. 35, step 3). Additionally, ERK 1/2 is an upstream MAPK that 
controls CREB production of dynorphin. As we have seen from our data morphine 
administration increases the expression of dynorphin by microglia/macrophages (Fig. 35, 
step 4). Dynorphin is a naturally occurring peptide that at low physiological levels has 
antinociceptive properties. However, based on the literature, we predict that the supra-
physiological concentration of dynorphin induced by microglia/macrophages increases 
the vulnerability of already stressed neurons. This inflammation-induced stress causes 
neurons to express “eat me” markers that signal M1 microglia to phagocytize them (Fig. 
35, step 5). Simultaneously, as morphine is increasing neuronal vulnerability through the 
release of dynorphin and pro-inflammatory cytokines, morphine activation of TLRs on 
M1 microglia can induce them to change their function and engage in phagoptosis of 
stress-but-viable neurons. This process furthers the increase of neuronal cell death that 
occurs with SCI and delays locomotor recovery in rats.  
The literature and data discussed in this document highlights the ongoing challenge 
to understand complex opioid-immune interactions that can influence the rate of recovery 
of patients living with SCI. We propose that understanding the extent to which morphine 
can alter key immune functions like upregulation of pro-inflammatory cytokines, release 




will establish a strong scientific framework to advise alternative strategies for pain 
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